Clinical Digest: Recent Clinical Trials on HPV (2026-04)
To assist researchers and healthcare practitioners in staying up-to-date with the latest advancements in clinical research, the Clinical Digest Team has compiled a comprehensive list of recent clinical trials related to HPV. These trials are organized by their release dates for your convenience. (Last updated on: 2026-04-06)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: Recent Clinical Trials on HPV (2026-04)
| Clinical Trial | Contact(s) | Updated | |
|---|---|---|---|
| 1 | A Study on The Effectiveness of Large Language Model-Based Chatbot Interventions Among Female University Stdents in Improving HPV Vaccine Awareness, Intention and Vaccination Rates PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: This is an interventional study targeting female university students. The primary objective of the study is to evaluate the effectiveness of a vaccine chatbot in improving HPV vaccination rates. The secondary objectives are to evaluate the effectiveness in improving vaccine awareness and vaccination intention. All participants will be enrolled and randomly assigned to four groups: (1) vaccine chatbot plus scientific videos, (2) vaccine chatbot only, (3) scientific videos only, and (4) a control group (no intervention). The chatbot will provide immediate, validated answers to participants’ HPV vaccine-related questions. The scientific videos will cover content related to HPV vaccine safety, efficacy, … |
JUN ZHANG; | 2026-03-31 |
| 2 | Community Implementation of Urine HPV Test and Reflex DNA Methylation Test in Cervical Cancer Screening PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Aims: The project aims to explore the acceptability and feasibility of a self-sampling, urine-based HPV test (INDICAID HPV Urine Test) in a community setting, and the effectiveness of DNA methylation test for triaging high-risk HPV (HR-HPV) positive women to colposcopy examination compared to the current standard triage methods of cytology and HPV16/18 genotyping. There are two main hypotheses: 1. Urine self-sampling for HPV testing is an acceptable cervical screening option for women in the community. 2. Combining urine HPV testing with DNA methylation will increase the detection rate of high-grade lesions without increasing the colposcopy referral rate. Target participants: Women between the ages of 26-65 and have a history of sexual activity, not have a history of total hysterectomy or cervical cancer, not currently pregnant, not currently under treatment of cervical dysplasia or cervical cancer. This is a prospective study and women who are willing to undergo urine self-sampling for HPV test will be recruited from various communities, such as Specialist out-patient clinics of Queen Mary Hospital (Hong Kong), public areas in Queen Mary Hospital (such as lobby of out-patient clinics and corridors), District Health Centres, the Family Planning Association (FPA) clinics, Anticancer Society, Christian Action, Non Government Organizations (NGO), private organizations, and online. A total of 8,620 women are needed to be recruited to the study: approximately 4,700 onsite and 4,000 online. Study procedures: Self-collected urine samples from study subjects recruited in various communities will be examined using the INDICAID HPV Urine Test. Women with positive urine HPV results will undergo further testing, including urine DNA methylation and co-testing (cytology and HPV genotyping). They will be triaged to colposcopy when test results show clinical indications. The acceptability and feasibility of the urine test will be assessed by calculating the self-sample uptake rate and analyzing participant-reported questionnaires. The detection rate of high-grade lesions and the colposcopy referral rate will be compared between DNA methylation testing and the current standard methods. |
KAREN KAR LOEN CHAN; | 2026-03-12 |
| 3 | A Randomized Trial of Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates whether different types of digital health communication can increase parents’ intention to vaccinate their daughters against human papillomavirus (HPV) in Nigeria. HPV vaccination is recommended for girls aged 9-14 years and helps prevent cervical cancer, yet vaccination rates remain low. Parents of eligible, unvaccinated girls will be randomly assigned to receive one of several types of digital content delivered online. These include: (1) a short chatbot conversation based on motivational interviewing principles, (2) an interactive game designed to help parents recognize and resist common forms of vaccine misinformation, … |
UNIVERSITY OF PENNSYLVANIA | 2026-03-27 |
| 4 | A Randomized, Active Controlled, Assessors-blind Trial to Establish Non-inferiority of Immunogenicity of A Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to The Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, … |
RAVIVARMAN LAKSHMANASAMY; | 2026-03-24 |
| 5 | The Effect of Health Belief Model-Based Education on Mothers of Children Aged 9-15 Years: Impact on HPV Knowledge Level and Child Vaccination PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to examine the effects of education provided to mothers of children aged 9-15 within the framework of the Health Belief Model on mothers’ knowledge, attitudes, and behaviors about Human Papillomavirus (HPV), and their willingness to have their children vaccinated against HPV. The study, designed with a randomized controlled experimental design, will be conducted at three different Family Health Centers in Gaziantep and will consist of both experimental and control groups. Mothers in the experimental group will receive a three-session visually supported education program prepared by Yıldız USCA, … |
YILDIZ USCA; | 2026-03-05 |
| 6 | SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer: A Phase II Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Oropharyngeal cancer (OPC) is the most common type of head and neck cancer. The current standard treatment for this cancer is radiotherapy (RT) of the tumour and lymph nodes of both sides of the neck, combined with concurrent chemotherapy for advanced stages. Even though a small proportion of patients with this cancer have involvement of the lymph nodes of the neck on the opposite side of the tumour (contralateral involvement) or involvement of the lymph nodes on both sides of the neck (bilateral involvement), bilateral radiotherapy is performed due to the risk of contralateral microscopic involvement, … |
UNICANCER | 2026-03-24 |
| 7 | Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya (ENHANCE LINKAGE) PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Background In sub-Saharan Africa (SSA), human papillomavirus (HPV) and HIV create a dual burden of disease that causes significant morbidity and mortality in the form of cervical cancer (CC). Women living with HIV (WLWH) have a six-fold higher risk of developing precancerous lesions that persist and progress to CC, which is the leading cause of cancer mortality among women in Kenya. Significant support from the Go Further campaign, represented by donors such as the President’s Emergency Plan for AIDS Relief (PEPFAR), the George W. Bush Institute, UNAIDS, Merck, and Roche, … |
MICHAEL H CHUNG; | 2025-12-19 |
| 8 | Towards An Understanding of Barriers and Delays in The Diagnosis of Anal Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study examines care pathways in 300 patients with anal squamous cell carcinoma to identify barriers and delays in diagnosis, assess the impact of screening and access to care, and improve awareness, screening practices, and early diagnosis. |
CENTRE HOSPITALIER INTERCOMMUNAL CRETEIL | 2026-03-06 |
| 9 | Developing A First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After Vaccination With The Gardasil-9 HPV Vaccine – A Non-randomized Open-label Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The current study is an open-label, non-randomized, longitudinal exploratory trial using the licensed Gardasil 9 (9vHPV) vaccine in an off-label context to investigate biological and immunological outcomes in human papillomavirus type 16 (HPV16) positive women. Two doses of the licensed Gardasil 9 vaccine will be administered to approximately 50 women between 18 and 45 years old, who test positive for HPV16 DNA at baseline using a type-specific quantitative PCR assay, … |
WIEBREN TJALMA; | 2026-03-27 |
| 10 | The STOP-HPV Scale Up Study PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: Human papillomavirus (HPV) causes 35,900 US cancer cases per year, 4,000 deaths, and $4 billion in can In this study, the investigators will conduct a 3-arm clustered randomized controlled trial (RCT) in an estimated 72 practices from up to 8 health systems to evaluate the effectiveness and cost effectiveness of two potentially scalable implementation strategies (based on prior work) to increase the initiation of HPV vaccine against a usual care (control) arm. The intervention arms are 1) online provider communication training only (STOP-HPV-Online and 2) online provider communication training plus a Learning Collaborative, with performance feedback, … |
PETER G SZILAGYI; | 2026-02-27 |
| 11 | Elective Neck Dosing in Low Risk Oropharyngeal Human Papillomavirus-Related Cancer Treatment (ENLIGHT): A Single Arm Prospective Phase II Assessing 30 Gy Elective Neck Dose PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This clinical trial evaluates how decreasing the dose of radiation to the elective neck (areas of lymph nodes not directly involved in the cancer) impacts treatment outcomes in patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Radiation therapy plays an important role in the treatment of HPV-related oropharyngeal cancer, but it also causes significant toxicities. Given the significant toxicities associated with treatment, and the excellent outcomes of HPV-related oropharyngeal cancer, … |
LAILA A GHARZAI; | 2025-09-17 |
| 12 | Feasibility of Community-based Distribution of HPV Self-Collection Kits for At Home Cervical Cancer Screening PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is testing and implementing an equity-focused, community-based intervention that improves women’s access to cervical cancer screening and adherence to follow up after an abnormal result. The study’s objective is to assess and compare the feasibility of different methods of distributing at-home HPV testing kits for cervical cancer screening among individuals who are under-screened. |
MICHELLE SILVER; | 2026-03-06 |
| 13 | Probiotics to Treat HSIL and Reduce Persistent High Risk HPV Infection in Women and Men Living With HIV PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population |
JOEL PALEFSKY; | 2026-02-02 |
| 14 | Improving Cervical Cancer Prevention Among Women Living With Chronic Conditions. Aim 3: Assess The Feasibility and Acceptability of The PINPOINT Intervention PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Our overarching goal is to adapt and test the PINPOINT intervention -PatIent Navigation for the Prevention of CervIcal CaNcer inTervention. We will test the PINPOINT intervention among patients with high-risk profiles for cervical cancer who do not meet the recommended screening for cervical cancer. |
UNIVERSITY OF FLORIDA | 2026-01-20 |
| 15 | A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in The Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a prospective, multicenter, single-arm clinical trial investigating Becotatug Vedotin in combination with Zimberelimab for the treatment of patients with recurrent and metastatic cervical cancer, vulvar cancer, and vaginal cancer. A total of 30 patients are expected to be enrolled. The study consists of a screening period (within 28 days), a treatment period, and a follow-up period (safety follow-up and survival follow-up). Trial treatment will continue until the patient has received Becotatug Vedotin for 1 year, or until disease progression, unacceptable toxicity, withdrawal of informed consent, or death, … |
GUILING LI; | 2026-02-20 |
| 16 | POINT of CARE – Providing An Innovative New Triage and Treatment Strategy for Cervical Cancer Screening Efficiency PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates a modified two-probe thermal ablation protocol using the IRIS™ device and retrospectively assesses an AI-based Automated Visual Evaluation (AVE) triage algorithm among HPV-positive women in El Salvador. The primary objective is to estimate 1-year cure rates of CIN2+ following treatment. A secondary objective is to evaluate the diagnostic performance of AVE compared with histopathology. |
KARLA ALFARO; | 2026-03-11 |
| 17 | Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to conduct a randomized controlled trial to evaluate the effectiveness of same-day HPV-based screen and treat among women living with HIV (WLH) in La Romana, Dominican Republic. With cervical cancer being a leading cause of cancer-related deaths in women living with HIV, and cervical cancer deaths being preventable through screening and early detection, this project seeks to identify factors associated with the successful implementation of the Screen, Triage, and Treat approach to inform future implementation and scale-up. |
REBECCA SCHNALL; | 2026-02-04 |
| 18 | A Randomized Trial of MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: MODUCIN-1 (MODUcare for CIN1) is a prospective, single center, open-label, randomized trial that its purpose is to compare MODUCARE versus Wait-and-See Approach for the regression rate of histologically proven low-grade Cervical Intraepithelial Neoplasia (CIN1). |
DIMITRIOS ZOUZOULAS; | 2026-02-05 |
| 19 | Expanded Use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of Two Probes (PRO Cohort) for Cervical Cancer Prevention in Women Living With HIV PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. In Kenya, the estimated incidence rate of cervical cancer is 31-33 per 100,000 women per year among women without HIV and approximately 70-100 per 100,000 among WLWH. The proposed study will evaluate the feasibility, acceptability, … |
MARGARET M. MADELEINE; | 2026-03-12 |
| 20 | An Investigation in The Use of Curcumin Topical Herbal Agent for The Treatment of Cervical Intraepithelial Neoplasia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to see if curcumin can suppress HPV infection in women with low-grade squamous intraepithelial lesions (LSIL) disease or treated high-grade squamous intraepithelial lesions (HSIL) disease. This study plans to explore the effect of curcumin as a potential medical treatment in HIV-uninfected and infected women with mild precancerous lesions of the cervix or recently treated high-grade precancerous lesions at risk for persistent HPV infection. About 200 women with low-grade precancerous lesions of the cervix or recently treated high-grade precancerous lesions will be enrolled to either insert 2000 mg of curcumin capsules in their vagina once a week or placebo after undergoing colposcopy or loop electrosurgical excision procedure (LEEP). They will have a repeat visit in 6 months where they will undergo a Pap smear and HPV test to determine if there are higher rates of HPV clearance after curcumin administration. If HPV is present or the Pap smear is abnormal, patients will then undergo colposcopic examination to evaluate cervical histology. |
LISA FLOWERS; | 2025-10-29 |
| 21 | Uniting Trusted Community Messengers to Improve Access to Cervical Cancer Screening in Rural North Carolina Aim 3 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to test the feasibility and acceptability of a multi-level, community-engaged intervention to increase access to cervical cancer screening using human papillomavirus (HPV) self-collection (HPVSC) outreach among women living in a high-risk rural county and to improve navigation for follow-up screening. A one-group intervention evaluation design will be used to pilot test feasibility and acceptability and to assess the proportion of women who return HPVSC kits and test HPV-positive. At the community level, local community-based organizations (CBOs) will serve as HPVSC kit distribution sites. At the individual level, … |
LISA MANSFIELD; | 2026-02-20 |
| 22 | PVX4 for The Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this Phase 2 study is to compare the effects of administering the PVX4 combination device biologic product (pBI-4 DNA vaccine via electroporation-mediated intramuscular delivery with the TriGrid™ Delivery System) in patients with biopsy-confirmed, human papilloma virus (HPV) 16-associated high grade cervical intraepithelial neoplasia (CIN2/3) as compared to the administration of placebo. |
JUAN D QUNIONES; | 2026-03-09 |
| 23 | Effectiveness of A Non-Invasive Treatment Using A Vaginal Gel in Promoting HPV Clearance and Regression of Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate whether a Coriolus versicolor-based vaginal gel promotes regression of CIN1/CIN2 and facilitates HPV clearance in women aged 30-50 years diagnosed with CIN1 or CIN2 and HPV. In addition, the study will assess patient satisfaction, treatment compliance and characterize the vaginal microbiome. The primary outcomes therefore is: * the regression of the cervical dysplasia from baseline to the follow-up (6 months), which will be assessed through either liquid-based cytology and/or histopathology (biopsy). * HPV clearance from baseline to follow-up (6 months) In this randomized controlled study, … |
VIBE MUNK BERTELSEN; | 2026-03-04 |
| 24 | Effect of A Dietary Supplement Containing EGCG, Folic Acid, Vitamin B12 and Hyaluronic Acid in Supporting Male Genital Balance in Subjects Exposed to HPV Risk PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Pilot interventional study aimed at evaluating the effect of a dietary supplement containing EGCG, vitamin B12, hyaluronic acid, and folic acid on the maintenance of physiological balance of the genital mucosa and natural defenses of the male genital tract, as well as on the maintenance of HPV-DNA test negativity, in subjects undergoing natural procreation pathways. The study will also assess the potential support of sperm parameters, reproductive well-being of the couple, … |
DOMENICO MILARDI; | 2026-01-08 |
| 25 | Evaluation of The Effect of A Dietary Supplement Based on EGCG, Vitamin B12, Hyaluronic Acid, and Folic Acid on The Maintenance of Physiological Balance and The Natural Defenses of The Male Genital System in Subjects Exposed to HPV Infection PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized pilot interventional study aimed at evaluating the effect of a dietary supplement containing EGCG, vitamin B12, hyaluronic acid, and folic acid on the maintenance of physiological balance and natural defenses of the male genital tract in subjects exposed to HPV infection and seeking care for infertility at natural procreation centers. The study includes 48 couples (96 participants) recruited at the International Scientific Institute Paolo VI of the A. Gemelli Policlinico, randomly assigned to two groups: 24 couples in which both partners receive one oral tablet per day of the supplement for 6 months, … |
DOMENICO MILARDI; | 2026-01-15 |
| 26 | A Randomized, Triple-blind, Placebo-controlled, Parallel Clinical Trial to Investigate The Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused By HPV PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to investigate the safety and efficacy of Papillex® on the regression of abnormal cervical cells caused by HPV in women with a cervical intraepithelial neoplasia (CIN) 1 or 2 diagnosis. The main question it aims to answer is: Is there a difference in the proportion of participants with a regression in CIN based on histology or cytology from baseline at day 180 between Papillex® and placebo? Participants will be asked to consume Papillex® or placebo for 180 days, complete questionnaires, a PAP smear, HPV test, and colonoscopy (where applicable). |
DAVID CROWLEY; | 2026-03-05 |
| 27 | Study To Compare The Efficacy Of Cervical Cytology With Molecular Screening In The Detection Of Reactive Cellular Changes In The Cervix In An Open Population Related Papers Related Patents Related Grants Related Experts Highlight: This study compares the efficacy of cytology (Pap smear) with the molecular screening in their ability to detect reactive cellular changes in the cervix among an open population |
LEOPOLDO E GATICA-GALINA; | 2026-03-03 |
| 28 | The Effect of Parent Education on Human Papillomavirus Vaccination Intention: A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and is the primary cause of cervical cancer. According to World Health Organization (WHO) systems, there were approximately 660,000 new cases of cervical cancer and 350,000 deaths in 2022. In Turkey, the prevalence of cervical cancer was reported as 8,761 in the last five years. HPV vaccines are safe and effective in preventing HPV transmission and cancer and are included in 147 national immunization programs; However, … |
KTO KARATAY UNIVERSITY | 2026-03-03 |
| 29 | Comparison of Clinic-based Versus Clinic-plus Community Outreach-based Strategy Via HPV Self-Collection to Increase Uptake of Cervical Cancer Screening Among Women Living With HIV: A Cluster Randomized Trial (CASCADE-3001-A) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This Clinical Trials Network for Human Immunodeficiency Virus (HIV)-Associated Cervical Cancer Screening and Treatment Optimization (CASCADE) -3001-A trial aims to assess how the introduction of a community-health-worker-facilitated model, in addition to the existing static clinic-only model, influences the rates of cervical cancer screening uptake among women living with HIV (WLWH). This study involves offering HPV self-collection for cervical cancer screening to eligible WLWH. The ‘CASCADE’ Network is a clinical trials network aimed at improving cervical cancer screening, management, and pre-cancer treatment for WLWH, in various healthcare settings. The network will conduct implementation trials to improve the triage of HPV-positive WLWH, … |
JENNIFER SMITH; | 2026-02-27 |
| 30 | Study To Compare The Efficacy Of Cervical Cytology With Molecular Screening For Detecting Reactive Cellular Changes In The Cervix In An Open Population PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study compares how effective is the molecular screening (a blood test) using Pap smear as reference, that is, a comparison of these tests abilities to detect precursor lesions and cervical cancer among women of an open population |
LEOPOLDO E GATICA-GALINA; | 2026-03-18 |
| 31 | The Mother-Daughter Project: Inclusion of Difficult-to-reach Kenyan Families, and Studies of Factors Influencing The Immune Response to HPV Vaccination (Merck-4) PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This project serves to continue a community-based initiative, known as the Kenya Mother-Daughter Cervical Cancer Eradication Project, or the Mother-Daughter Project (MDP), in the Webuye region of Western Kenya. The MDP project, since its initiation in 2018, has sought to develop a framework for the eradication of cervical cancer through effective screening of adult women and through the vaccination of female children. This project specifically aims to collect additional data on the ability for HR-HPV testing to detect premalignant lesions of the cervix, especially in HIV-infected women, to investigate and identify barriers leading to non-participation in previous MDP efforts, … |
DARRON BROWN; | 2026-01-15 |
| 32 | Influence of Anti-Psoriatic Biologic Therapies Targeting TNF-α and Interleukins 17 and 23 on The Risk of Development and Recurrence of Anogenital Warts: A Retrospective and Prospective Study With An Exploratory Component on HPV Vaccination Acceptability (CONDYPSO) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to assess the impact of anti-TNF-α, anti-IL-17, and anti-IL-23 biologic therapies on the risk of development or recurrence of anogenital warts (AGW) in patients with moderate to severe psoriasis. By modulating systemic and mucosal immunity, these treatments may alter host defenses against human papillomavirus (HPV) infections, which are responsible for AGW. In particular, inhibition of Th1 pathways (by anti-TNF-α) and Th17 pathways (by anti-IL-17 and anti-IL-23), both central to the antiviral response, may reduce local production of pro-inflammatory cytokines (such as IFN-γ, IL-17, and IL-22), decrease the activity of CD8+ cytotoxic T lymphocytes, … |
JONATHAN KRYGIER; | 2026-03-18 |
| 33 | Implementation of HPV Testing in Patients After Radiotherapy for Cervical Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The HART (HPV After chemoRadiotherapy) study is a prospective multicenter observational trial designed to evaluate the clinical utility of HPV testing in the follow-up of patients treated with definitive chemoradiotherapy (CRT) for cervical cancer. Current surveillance after CRT relies mainly on clinical examination and imaging, … |
DAVID CIBULA; | 2026-03-25 |
| 34 | Secondary Cervical Cancer Prevention of Vulnerable Women With Human Papillomavirus (HPV) and Human Immunodeficiency Virus (HIV) Co-infection in India PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually. With high-risk human papillomavirus (HR-HPV) as the causative agent for CC, one risk factor that places women at high risk for CC is human immunodeficiency virus (HIV), as impaired immune response against Human papillomavirus (HPV) may result in persistent HR-HPV infection, a critical risk factor for progression of HPV-related cervical oncogenesis. Progression of precancerous lesions among women living with HIV (WLH) is also associated with: 1) lack of HPV screening; … |
ADELINE NYAMATHI; | 2026-02-23 |
| 35 | Evaluation of The Efficacy & Safety of Topical Ivermectin Alone or in Combination With Microneedling As Novel Therapeutic Options for Cutaneous Non-genital Warts Versus Topical Salicylic Acid ؛ Randomized Controlled Clinical Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: To compare between the efficacy and safety of topical ivermectin alone, microneedling with topical ivermectin and topical salicylic acid in treatment of cutaneous warts. topical ivermectin 1% will be applied on warts whole night clinical assessment will be done every 2 weeks Microneedling will be performed on the lesion using a microneedling pen type device with a 1-cm tip diameter at a 2-mm depth setting for 2-3 minutes until pinpoint bleebing occurs 1 mL of topical ivermectin 1% will be applied on to the wart tissue. Sessions: Sessions will be performed every 2 weeks until complete cure or for maximum 6 sessions (total 3 month) |
AYA MOHAMED SAYED ABDELAZIZ; | 2026-02-09 |
| 36 | A Pilot Study of CUE-101 in Combination With Pembrolizumab in Subjects With Newly Diagnosed, Locally Advanced HPV-16 Associated Head and Neck Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A\*0201-positive treatment naive participants with locally advanced, unresectable HPV-16 associated head and neck squamous cell carcinoma (HNSCC). |
SARA PAI; | 2026-03-19 |
| 37 | HPV Vaccination and Infectivity Reduction in HPV-positive Women PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, open-label trial, to assess whether a single dose of HPV nonavalent vaccine, administered to HIV uninfected, unvaccinated women with high risk HPV16/18/31/33/45/52 or 58 can decrease the infectivity of shed HPV viruses. Our hypothesis is that vaccination will have little or no impact on HPV sample positivity by DNA PCR since the viral particles will continue to be produced and released, but that particles will be neutralized by vaccine-induced antibodies, thereby reducing their infective capacity. Cervical samples will be collected at randomisation and at 6 months, to compare infectivity of shed HPV viruses. |
MIQUEL ANGEL PAVON RIBAS; | 2026-02-11 |
| 38 | A Randomized, Observer-Blind, Placebo-Controlled, Proof-of-Concept Study to Assess The Safety, Tolerability and Immunogenicity of A Bivalent Human Papillomavirus (HPV) Vaccine in 9 and 15 Month Old Infants and Toddlers, 2-5 Year Old Children and An Open Label Single Dose Study in Young Unmarried Females Aged 15-20 Years in Ghana PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized observer-blind placebo-controlled proof-of-concept study with the aim to assess the safety and tolerability, and the immunogenicity of a bivalent HPV vaccine administered in healthy infants and toddlers (9- and 15-month-olds) comparing them to an immune-bridging population of 15-20-year-old unmarried females in an open label study in Ghana at the Dodowa Health Research Center. |
GEORGE ARMAH; | 2026-01-30 |
| 39 | The Effect of A Transtheoretical Model-Based Educational Intervention on First-Year Nursing Students’ HPV Knowledge, Health Beliefs, and Vaccination Behavior Intentions PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to examine the impact of a structured educational program based on the Transtheoretical Model (TTM) on HPV knowledge, health beliefs, and vaccination behavioral intentions among first-year nursing students. The study will also evaluate how the intervention affects students’ HPV vaccine readiness compared to the TTM. The primary questions addressed by the study are: * Does the TTM-based educational intervention increase students’ knowledge about HPV and the HPV vaccine? * Does the program change students’ health beliefs regarding susceptibility, severity, benefits, … |
MÜJDE KERKEZ; | 2026-03-27 |
| 40 | Multilevel Peer-to-Peer HPV Vaccination and Wellness Educational Program in School Based Health Centers PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: School-based health centers (SBHCs) are an important setting to improve health through detecting, managing and preventing chronic illness. Too few people are vaccinated for the human papillomavirus (HPV), which can prevent tens of thousands of deaths from cancer each year. PEER will evaluate a program to increase health and wellness and the use of SBHCs for primary and preventive care. If successful, PEER could significantly increase the use of SBHCs, and decrease HPV-associated cancers and, thus, reduce the burden of cancer in the United States. |
AMANDA PETRIK; | 2026-03-06 |
| 41 | Women’s HPV Education and Its Effects on Knowledge Levels, HPV Screening Behaviors, and HPV Vaccination Uptake: An Interventional Education Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Type of Study: This study was planned to be an observational study. Purpose of the Study: To evaluate the impact of HPV education given to women on their knowledge levels and HPV screening and vaccination.The main question\[s\] it aims to answer \[is/are\]: H1: There is a difference in the mean Human Papillomavirus (HPV) Knowledge Scale score between the intervention group women who participated in Human Papillomavirus (HPV) education and the control group women. H2: There is a difference between the intervention group women and the control group women in terms of their participation in HPV screening tests. H2: There is a difference between the intervention group women and the control group women in terms of their HPV vaccination status. Participants Participants will be assigned to a control and intervention group. Online training will be provided to the intervention group, and the results of the training will be reported. |
GIZEM BILMEZ; | 2026-01-22 |
| 42 | COUPLES AND MICROBIAL DIVERSITY PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Couples and Microbial Diversity (CLARITY) – study is a prospective study that investigates the risks and dynamics of different microbes and transmission among couples to optimize the prevention and control strategies as well as improvement for infertility treatments. The study will be conducted at the Infertility Clinic of Tampere University Hospital, Tampere Finland; … |
KAROLINA LOUVANTO; | 2026-01-02 |
| 43 | SCREEN-HPV: Blood Biomarkers Based Screening for HPV-driven OPC PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of our study is to demonstrate that it is possible to detect and treat human papilloma virus (HPV)-related oropharyngeal cancers (OPC) early using simple blood tests. The success of this strategy will be evaluated by the number of participants positive for both HPV16-E6 serology and HPV circulating tumor DNA (ctDNA) whose early management has allowed the detection of a cancerous lesion and/or whose HPV ctDNA results have normalized after surgical intervention. If this study is conclusive, it could pave the way for the implementation of a national screening strategy for HPV-related OPC. |
HAÏTHAM MIRGHANI; | 2025-09-19 |
| 44 | A Hybrid Type III Effectiveness – Implementation, Pragmatic Intervention Trial for Cervical Cancer Screen and Treat in Mozambique PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This proposal directly addresses the ability to safely scale-up a Screen-Triage-Treat approach to cervical cancer screening. The investigators propose to capitalize on a pool of screen-eligible women accessing routine care within targeted human immunodeficiency virus (HIV) care and treatment services. The primary outcome of interest is the number of women screened and the proportion of screen-positive women undergoing treatment. Secondary outcomes will focus on other implementation outcomes, and if successful, will be utilized to inform future research to take this approach to scale across Mozambique. |
D. TROY MOON; | 2025-12-17 |
| 45 | Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical HSIL/CIN2 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates the efficacy and safety of ALA-PDT versus LEEP in treating cervical HSIL/CIN2, aiming to demonstrate non-inferiority in clinical efficacy. |
SECOND AFFILIATED HOSPITAL SCHOOL OF MEDICINE ZHEJIANG UNIVERSITY | 2025-12-29 |
| 46 | Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical Low-grade Squamous Intraepithelial Lesions With HPV16/18 Infection PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This multicenter, prospective trial assesses ALA-PDT versus observation for efficacy and safety in treating cervical LSIL with HPV16/18 infection. |
SECOND AFFILIATED HOSPITAL SCHOOL OF MEDICINE ZHEJIANG UNIVERSITY | 2025-12-29 |
| 47 | IMVAHA: Improving Menstrual and VAginal Health for All PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A three-period crossover trial will study the effects of short-term use of 3 menstrual products (menstrual pad, tampon, menstrual cup) on the bacterial composition of the vaginal microbiome in three countries (Peru, Cameroon, and Switzerland). Each crossover period consists of two menstrual cycles, thus resulting in a 6-month trial. Participants will be randomly assigned to one of 6 exposure sequences (different order of products per sequence); in each sequence, … |
SONJA MERTEN; | 2026-01-08 |
| 48 | Human Papillomavirus Self-Sampling Options to Promote Equity (HOPE) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is testing a new way to help people who are unhoused get screened for cervical cancer. Cervical cancer can often be prevented if it is found early. Many people who lack stable housing usually do not receive regular screenings. Through this project, the investigators will bring screening to community locations in Tucson, Arizona, using a mobile health unit (MHU) from the University of Arizona (UA) and El Rio Health. At these sites, participants will receive easy-to-understand education about cervical cancer, learn how to collect their own sample for human papillomavirus (HPV) testing, … |
DAN THEODORESCU; | 2025-10-29 |
| 49 | Biomarker Driven Phase 1/1b Trial of Decitabine and Nivolumab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head and Neck PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This research study is for people who have recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has been confirmed by tissue or cell analysis and is considered incurable with local treatments. People who are eligible to receive anti-PD-L1 therapy as a first line treatment and whose primary tumor is located in the oral cavity, oropharynx, hypopharynx, or larynx, may be eligible to participate. The purpose of this study is to evaluate the immunogenicity of decitabine in combination with nivolumab, … |
KYUNGHEE BURKITT; | 2025-10-15 |
| 50 | Immunogenicity and Safety of Sequential Bivalent and 9-Valent Human Papillomavirus Vaccine Immunization in Girls Aged 9-14 Years PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to assess the immunogenicity and safety of a sequential 2vhpv to 9vhpv immunization schedule in girls aged 9-14 years |
SHENYU WANG; | 2025-12-15 |
| 51 | Prospective, Randomized, Cluster-controlled, Multicenter Study to Evaluate The Impact of An HPV Primary Prevention Intervention on HPV Vaccination Rates Among Adolescents in The AuRA Region PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Human papillomaviruses (HPV) are very common contagious viruses: approximately 70% of men and women will be infected during their lifetime. Vaccination, recommended since 2007 for girls and since 2021 for all young people aged 11 to 14 (with catch-up vaccination possible up to age 26), remains insufficiently followed. Today, only 40.7% of adolescents are vaccinated in France, and the Auvergne Rhône Alpes region remains below the targets (47.5% for girls and 12.3% for boys). This is still far from the national target of 80% vaccination coverage by 2030, … |
AMÉLIE WEBER; | 2026-02-17 |
| 52 | The Effect of Delivering HPV Education Through Different Methods on Young Women’s Intention to Receive The Vaccine: A Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Detailed Description Human papillomavirus (HPV) is one of the leading causes of cervical cancer and can be prevented by vaccination. However, HPV vaccination rates among young women are low, largely due to insufficient knowledge and misconceptions about HPV and the vaccine. Therefore, … |
EMEL GÜÇLÜ CİHAN; | 2026-02-19 |
| 53 | Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to test two commercially available technologies for their ability to detect treatment response in patients with cervical cancer following surgery, radiation, and chemotherapy: one based on polymerase chain reaction (PCR; NavDx) and the other on branched DNA (Quantivirus HPV \[DNA\]). A 9-month feasibility study will be performed to examine the side-by-side utility of both NavDx and Quantivirus HPV DNA assays in predicting cervical cancer treatment response. These tests could prove to be highly sensitive methods for evaluating minimal residual disease and for quantitation of response to surgery, radiation, … |
DAVID IGLESIAS; | 2026-02-12 |
| 54 | Accelerating Adoption of Patient-centered Cervical Cancer Screening and Treatment Linkage in Kenya PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to test the use of a multi-component care strategy (DADA LINK) designed to improve cervical cancer screening and linkage to treatment. The duration of the trial is 12 months, with a 6-month follow-up period to evaluate intervention costs and measure maintenance of the care strategies. Study staff at each clinic will abstract data on cervical cancer screening and triage/treatment. Clinics randomized to the intervention arm will have care coordinators who motivate clinic staff to adhere to cervical cancer care guidelines, conduct patient exit surveys to assess intervention fidelity, … |
ROSE J KOSGEI; | 2026-01-12 |
| 55 | H.Pylori Infection Among Women With Recurrent Abortion of Unknown Cause PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: * Helicobacter pylori (H. pylori) infection affects approximately one half of the world population and it is more prevalent in developing countries. This microorganism colonizes the stomach. Typically, it is acquired during childhood and causes asymptomatic chronic infection. A small portion of H. pylori infected subjects develop peptic ulcers and gastric carcinoma, usually during late adulthood. (1,2) * Some studies show a relationship between H.pylori and pregnancy-related disorders, such as fetal growth defects and malformations, miscarriage and, more recently, … |
MOSTAFA GAMAL AHMED MOSTAFA; | 2025-12-19 |
| 56 | Concordance and Acceptability of Self-screening Versus Screening By A Healthcare Professional for HPV, A Risk Factor for Anal Cancer, By Swab in People Living With HIV PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Anal canal cancers are on the increase in France, with around 2,000 new cases per year. These lesions can be detected by directed biopsies or smear tests. The incidence rate of anal cancer is 30 times higher in people living with HIV than in the general population. According to a recent study, the risk of anal cancer is highest in this population, but is also high in heterosexual men over 30 and women over 30. However, the proposal of a proctological examination in this population is not systematic. In France, there is no HPV screening for people living with HIV, … |
KEVIN DIALLO; | 2025-12-11 |
| 57 | Facts Tell… and With Stories Sell? Combining Viewer-tailored Personal HPV Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine Uptake PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study will compare the use of informational videos only, personal story videos only, and the combination of both, to see which is most effective in increasing HPV vaccination. |
DANIEL SALMON; | 2026-02-13 |
| 58 | NCI Cervical Cancer ‘Last Mile’ Initiative ‘Self-Collection for HPV Testing to Improve Cervical Cancer Prevention’ (SHIP) Trial LMI-001-A-S04 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. HPV is known to cause a variety of cancers including cervical cancer. Even though there are ways to detect cervical cancer, … |
VIKRANT V SAHASRABUDDHE; | 2026-02-17 |
| 59 | Tongue-out Radiation Therapy (TORT) for The Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Our institution recently began incorporating a novel tongue-out radiation therapy (TORT) technique for patients with head and neck tumors at particular subsites (oropharynx, larynx, hypopharynx). Protruding the tongue, i.e. tongue-out position, induces anatomical changes that facilitate decreased radiation dose to the oral tongue and PCM. The long-term goal is to determine whether TORT results in reduced severity and faster recovery from acute treatment-related toxicities (particularly mucositis, dysphagia, and dysgeusia) and improved long-term swallowing function and taste compared to traditional tongue-in RT for patients with HNC. |
YVONNE MOWERY; | 2025-12-17 |
| 60 | A Randomized, Open-label, Non-inferiority Phase IIIb Clinical Trial to Evaluate The Immunogenicity Age/Schedule Bridging Between Adolescent Girls Aged 9-14 Years Receiving A 2-dose Regimen or Adolescent Girls Aged 9-17 Years Receiving A 3-dose Regimen of A Quadrivalent Recombinant Human Papillomavirus (HPV) Vaccine (Hansenula Polymorpha) and Women Aged 18-35 Years PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This vaccine was jointly developed by Chengdu Institute of Biological Products Co., Ltd. and National Vaccine and Serum Institute, China, is co-sponsoring this clinical trial. This trial plans to enroll 1,800 female subjects aged 9-35 years, 450 in each of the 18-25 years old 3-dose group, 26-35 years old 3-dose group, … |
NATIONAL VACCINE AND SERUM INSTITUTE CHINA | 2026-01-23 |
| 61 | Stories to Prevent (StoP) HPV Cancers: A Communication Intervention to Increase HPV Vaccination Among Diverse Populations PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized controlled trial (RCT) evaluates the association of a narrative communication intervention on human papillomavirus (HPV) vaccination rates among 9- to 12-year-olds. The intervention is a brief video from local cancer survivors narrating their stories with an HPV-related cancer diagnosis and recommending the HPV vaccine for cancer prevention. RCT participants will be the parents (n=200) of children ages 9-12 who have not initiated HPV vaccination. Participants will be randomized (1:1) to our intervention or control (placebo video) one week before their child’s next primary care visit. Our primary outcome is HPV vaccine initiation (first dose of the HPV vaccine series) among children ages 9-12 at the time of the wellness visit. The study also explores the effect of narratives on theory-based mediators of HPV vaccination, including parents’ cognitive (e.g., risk perception) and emotional reactions (e.g., hope, anticipated regret). |
WILLIAM CALO; | 2026-02-24 |
| 62 | The Effect of Human Papillomavirus Education Provided to Women on Their Level of Knowledge Regarding Human Papillomavirus PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This interventional study aims to evaluate the effectiveness of an educational program on women’s knowledge of Human Papillomavirus (HPV), HPV vaccination, and screening. HPV is a major public health concern worldwide and a leading cause of cervical cancer. Although cervical cancer is preventable through vaccination and early screening, HPV awareness among women remains limited in Türkiye. Educational interventions are therefore essential to improve knowledge and promote preventive health behaviors. The study population consists of 110 women attending courses at the Suzan and Abdulhakim Bilgili Public Education Center in Onikişubat, Kahramanmaraş, Türkiye, … |
FATMA KESKIN TÖRE; | 2025-11-17 |
| 63 | A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate The Efficacy and Safety of NWRD08 in Patients With HPV16/18-Positive Cervical High-Grade Squamous Intraepithelial Lesion (HSIL) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD08 administered by intramuscular (IM) injection followed by electroporation (EP) in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) associated with human papillomavirus (HPV) 16 and/or HPV18. |
NEWISH BIOTECH WUXI | 2026-02-17 |
| 64 | Artificial Intelligence-assisted Decision-making to Improve Women’s Participation to Cervical Cancer Screening in Occitanie Region-France PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This project looks to improve the return rate of HPV self-sampling (HPVss) as well as the management of women HPVss positive. |
FARIDA SELMOUNI; | 2026-03-27 |
| 65 | The Impact of A Mobile App-Supported Human Papilloma Virus and Breast Cancer Program on HPV Literacy and Breast Cancer Screening Beliefs PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to learn about the impact of a mobile application-supported education program on women’s HPV literacy and their beliefs regarding breast cancer screening. The main questions it aims to answer are: * Does a mobile application-supported program increase HPV literacy levels among women? * Does this intervention strengthen women’s positive beliefs and attitudes toward breast cancer screening? Researchers will examine how this holistic, … |
NİHAN TÜRKOĞLU; | 2026-03-13 |
| 66 | Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men – A Danish Prospective Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The incidence of anal cancer is increasing, particularly among high-risk groups such as men who have sex with men (MSM), especially those living with HIV. The lack of comprehensive screening programs results in delayed diagnosis and higher mortality. This project aims to establish a screening program for anal cancer in high-risk populations, with a specific focus on those most at risk. Using a prospective study design, the project will assess the effectiveness of early detection and prevention strategies to potentially reduce cancer incidence and improve survival rates. If an HPV-based screening method proves effective, … |
HELLE KIELLBERG LARSEN; | 2025-08-14 |
| 67 | Phase I Dose Escalation Study of The Use of ACU-D1, A Topical Proteasome Inhibitor in HPV Associated Vulvar and Perianal Lesions in People With HIV Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to test the maximum tolerated dose of ACU-D1 in HIV-positive people with HPV-associated vulvar and perianal lesions. The main questions it aims to answer are: * The maximum tolerated dose of ACU-D1 * Safety and tolerability of topical ACU-D1 * Whether topical ACU-D1 induces p53 and p53-mediated downstream signaling (including p21 induction) in HPV-related lesions * Whether topical ACU-D1 enhances markers of immunity in HPV-infected HIV-positive individuals Participants will be asked * To apply ACU-D1 on the lesions twice daily for 4 weeks * 3 biopsies will be performed at the screening and 3 at the end of 4 weeks. |
LISA FLOWERS; | 2025-08-06 |
| 68 | Uptake of HPV Self-sampling in Underserved Minority Women Using A Community Health Worker Model: Comparison of Evalyn Brush and Copan Floqswab PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Phase I: Validating self-collection kit by comparing their results with clinical Pap smear results in a cohort of 20 patients. Phase II: Evaluate the feasibility and acceptability of the CHW4CervicalHealth: Use of a self-collection kit to improve cervical health screening intervention aimed to promote HPV self-collection uptake among screening-eligible and under-screened ethnic minority women in the community. |
SANDRA DAYARATNA; | 2026-01-13 |
| 69 | PREVENT: Practice-based Approaches to Promote HPV Vaccination in The Safety Net – Randomized Controlled Trial (RCT) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study will serve as one of the first to develop and test the effectiveness of strategies to promote HPV vaccination among diverse rural parents and caregivers of children ages 9-17 years in the Mountain West. Once implemented into practice, … |
DEANNA KEPKA; | 2026-03-09 |
| 70 | Improving Cervical Cancer Screening Coverage Among Underscreened Women Aged 50 to 74 in Switzerland Using HPV Self-sampling Strategies: A Randomized Study – Breast Cancer-Related Approach for Increasing Cervical Cancer Screening PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of this clinical trial is to assess cervical cancer screening participation among under-screened women invited through organized breast cancer screening programs in Switzerland. This randomized trial will compare three arms: 1. Intervention group 1: Sensitization to Cervical Cancer (CC) screening Women will receive an awareness letter explaining the importance of cervical cancer screening, … |
JESSICA DI VINCENZO SORMANI; | 2025-12-22 |
| 71 | HPV Self-Collection in Novel Settings to Increase Cervical Cancer Screening PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This clinical trial evaluates whether offering human papillomavirus (HPV) self-collection for cervical cancer screening at Mayo Clinic Express Care clinics improves uptake of cervical cancer screening and receipt of appropriate follow-up care. Cervical cancer is preventable through vaccination, screening, and treatment of pre-cancerous conditions. However, cervical cancer screening rates have declined over the past 25 years, and an estimated 25% of women are unscreened or overdue for screening. Usual care at Mayo Clinic currently includes annual portal or letter communications in the form of scheduled outreach to request scheduling an appointment for cervical cancer screening, … |
KATHY L. MACLAUGHLIN; | 2025-10-30 |
| 72 | A Phase II Study of Volrustomig, Paclitaxel, and Carboplatin Followed By Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma . |
ARI ROSENBERG; | 2026-03-04 |
| 73 | Study for Prevention of Cervical Cancer in Spain PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The REVIVE study aims to analyze the current status of Human Papillomavirus (HPV) vaccination programs and cervical cancer screening strategies in Spain. Its objective is to gain a comprehensive understanding of the effectiveness of these preventive measures, as well as to identify the main barriers to access and the existing inequalities in care. The study will also examine the impact of misinformation on population engagement and on the overall equity of the prevention system. Despite significant advances in both vaccination and screening efforts, cervical cancer remains a major public health concern in Spain. In 2024 alone, … |
CLINICA UNIVERSIDAD DE NAVARRA UNIVERSIDAD DE NAVARRA | 2025-08-08 |
| 74 | HPV Vaccine Confident Families PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The objectives of the study are to pilot test a tailored intervention among Black families with adolescents. The hypotheses are that the study protocol will be feasible and messages tailored to parents’ needs will increase vaccine confidence and intention to vaccinate. |
RACQUEL KOHLER; | 2025-08-11 |
| 75 | Empowering Vietnamese Americans: A Culture-Centric Digital Storytelling Intervention to Boost HPV Vaccination PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn whether short videos can help Vietnamese American mothers decide to vaccinate their children against HPV (human papillomavirus). The study will explore: (1) which type of video is most effective in encouraging mothers to vaccinate their children; (2) how mothers perceive and engage with the videos; and (3) how many children receive the HPV vaccine after their mothers watch the videos. Participants will be randomly assigned to one of three groups: (a) watch four short digital stories about the HPV vaccine created by Vietnamese mothers; … |
ANGELA CHIA-CHEN CHEN; | 2025-09-10 |
| 76 | The Effect of Card Game Education on The Knowledge and Health Beliefs of Hearing Impaired Individuals About Human Papillomavirus (HPV): A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Health education is one approach to influencing individuals, groups, or communities to achieve better health. The literature indicates that increasing awareness of HPV, along with participation in early screening and vaccination programs, can positively influence attitudes and behaviors. Therefore, this research will be conducted to determine the effect of education using the card game method on the knowledge and health beliefs of hearing-impaired individuals regarding Human Papilloma Virus (HPV). |
SAKINE YILMAZ; | 2025-10-06 |
| 77 | Evaluation of A Vaccine Chatbot on HPV Vaccine Confidence and Hesitancy: A Randomized Controlled Trial and Implementation Science Study PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if a chatbot powered by artificial intelligence works to improve HPV vaccination among females aged 15 to 26 in China. A randomized controlled trial and implementation science study will be conducted targeting females as participants. The main questions it aims to answer are: 1. Does the vaccine chatbot influence women’s confidence, literacy, hesitancy, … |
ZHIYUAN HOU; | 2025-10-01 |
| 78 | A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 Alone or in Combination With PD-L1 T-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Squamous cell carcinoma is a type of cancer that can cause tumors on the head and neck (HNSCC). Even with treatment, less than 50% of people with certain types of HNSCC survive for 5 years. Objective: To test a new drug treatment (N-803 and pembrolizumab, … |
CHARALAMPOS FLOUDAS; | 2025-10-20 |
| 79 | Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Since the 2019-2020 school year, the province of Quebec (Canada) has been administering one dose of nonavalent (9vHPV) vaccine to students of all genders in Grade 4 of elementary school through the school-based program. Little data on the immunogenicity (antibody production) and long-term efficacy of a single dose of the vaccine are available, … |
CHANTAL SAUVAGEAU; | 2025-09-29 |
| 80 | Screening for Anal Cancer in MSM Using PrEP PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to learn more about anal cancer risk in men who have sex with men (MSM) who are using Pre-Exposure Prophylaxis (PrEP) to prevent HIV. Specifically, we want to check how common High-Grade Squamous Intraepithelial Lesions (HSIL) are in this group, how well anal swabs can screen for these lesions, … |
UNIVERSITAIR ZIEKENHUIS BRUSSEL | 2025-11-18 |
| 81 | A Randomized, Open-label Clinical Trial to Assess The Safety, Feasibility and Immunogenicity of Adjuvant PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy. |
STEPHANIE GAILLARD; | 2025-10-15 |
| 82 | Gynecological and Fertility Impact of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia Diagnosed in Adulthood (GYNEGRAFT) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Gynecological impact and infertility are major issues for women after allogeneic hematopoietic stem cell transplantation. The aim of the present study is to investigate the prevalence of gynecological complications after allogeneic hematopoietic stem cell transplantation for acute leukemia in adulthood. By conducting a single-center retrospective descriptive analysis, the prevalence, follow-up and treatment of gynecological complications -including premature ovarian failure, vulvovaginal graft-versus-host-disease, cervical pathology- will be analysed |
UNIVERSITY HOSPITAL BORDEAUX | 2025-12-16 |
| 83 | Screening for Anal Cancer and Precancer in Women With HIV (SANCA) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The main aim of the SANCA study is to evaluate the feasibility, cost-effectiveness, and acceptability of implementing international anal cancer screening guidelines for women living with HIV in Sweden, integrating health economic and patient-centered approaches. Secondly the investigators wish to investigate the predictive potential of DNA methylation markers for the clinical progression of precancerous anal lesions in women with HIV, combining prospective molecular biology analysis with clinical data from registries. |
CHRISTINA CARLANDER; | 2025-07-10 |
| 84 | A Pilot Randomized Controlled Study to Examine Feasibility and Preliminary Effectiveness of A Game-based Intervention in Promoting HPV Vaccination Among Vulnerable Youth to Prevent Cancers PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This proposed study aims to conduct timely research that promotes vaccine confidence and vaccination of one strongly recommended vaccine with suboptimal uptake rates: Human papillomavirus (HPV) in vulnerable and underserved youth aged 11-14. |
ANGELA CHIA-CHEN CHEN; | 2025-09-08 |
| 85 | An Open-Label, Two-Arm, Non-Randomized Clinical Study On The Safety And Efficacy Of Instantaneous CRISPR/Cas9 Gene Editing Therapy For Treating Chinese Patients With HPV-16-Related High-Grade Squamous Intraepithelial Lesions (HSIL) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is intented to evaluate the safety, and tolerability and preliminary efficacy of Instantaneous CRISPR/Cas9 Gene Editing Therapy (BD114 virus-like particle, also BD114) for the treatment of high-grade squamous intraepithelial lesions (HSIL) associated with HPV-16 infection. |
LONG SUI; | 2025-09-12 |
| 86 | Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Based on the trend that the incidence and mortality of cervical carcinoma among female cancers worldwide are increasing year by year, the investigators aim to develop a multi-epitope therapeutic vaccine capable of simultaneously activating humoral and cellular immune responses, which is achieved by fusing multiple T-cell epitope immunostimulatory proteins. To obtain information on functional T-cell epitopes to be included in the vaccine, the investigators conducted research starting from clinical cases. By collecting peripheral blood and cancerous tissues from clinical patients, the investigators isolated reactive T-cells and screened for information on T-cell epitopes of HPV antigens. |
ANHUI PROVINCIAL HOSPITAL | 2025-07-22 |
| 87 | HPV DNA Screening With Self-Collection Method and Its Management in The Context of Population-Based Cervical Cancer Screening Pilot Project in Indonesia PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to implement human papillomavirus (HPV) self-collection in Indonesia. |
WIDYORINI L HANAFI; | 2025-09-17 |
| 88 | A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. The intent of E7 TCR-T cell treatment is to shrink or eliminate tumors and thereby facilitate definitive therapy and increase overall survival. This study seeks to determine 1) if E7 TCR-T cells can be administered without undue delay in definitive treatment, 2) the tumor response rate to E7 TCR-T cell treatment, … |
CHRISTIAN HINRICHS; | 2026-02-27 |
| 89 | Comparing The Antibody and B Cell Responses Induced By 1- or 2-dose 9-valent HPV (9vHPV) Vaccination in Healthy Adults PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to answer the question: does 1-dose HPV vaccination generate the same immune responses compared to 2- or 3-dose HPV vaccination? This will be done by studying the immune response in blood, lymph nodes, and bone marrow. Human papillomaviruses (HPV) cause cancers (cervical, anal, oropharyngeal, vulvar, vaginal, and penile), and the current HPV vaccine is highly effective at preventing disease by HPV types that cause 90% of cancer cases. While this vaccine generates high levels of antibodies that last for \> 10 years, understanding of how this occurs is limited, … |
ERIN SCHERER; | 2025-08-20 |
| 90 | Cervical Cancer Screening Using Self-sampling Approach: Validation of Human Papillomavirus Self-sampling Kits Among Kazakhstani Women PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Prevention of cervical cancer is one of the priority areas of the Comprehensive Plan to Combat Cancer in the Republic of Kazakhstan for 2023-2027. High-risk human papillomavirus (HR-HPV) infections cause a wide variety of benign and malignant conditions, including cervical cancer. More than 90% of cervical cancer cases are attributed to HR-HPV infections, with HPV-16 and HPV-18 being reported to cause 70-75% of cases. At the present time, cervical cancer remains the fourth most prevalent cancer among women worldwide. Moreover, the majority of cervical cancer cases (90%) occur in low- and middle-income countries (LMICs), … |
NAZARBAYEV UNIVERSITY | 2025-08-08 |
| 91 | Transmission of Oncogenic HPV Infection Among Families PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of the Transmission of Oncogenic HPV Infection Among Families (TREVINO) study is to improve understanding of how high-risk human papillomavirus (HPV) infections are transmitted within families. The research focuses on transmission between sexual partners and between parents and children. It also examines how the various microbes may influence the persistence of HPV infections and the development of HPV-related cancers. The study will include up to 300 couples recruited from gynecology and ear, nose, and throat (ENT) clinics in Finland, as well as their children. Participants include individuals with persistent HPV infection, cervical precancer or cancer, … |
KAROLINA LOUVANTO; | 2025-06-25 |
| 92 | The Effect of Health Belief Model-Based Education and Motivational Interviewing on Human Papillomavirus (HPV) Infection Knowledge Level and HPV Vaccine Awareness Among Women PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the effect of an educational intervention based on the Health Belief Model (HBM) combined with motivational interviewing on women’s knowledge about Human Papillomavirus (HPV) infection and their awareness of HPV vaccination. The study will be conducted among women aged 18-45 who have not received the HPV vaccine. Participants in the intervention group will receive structured education and motivational interviews, … |
SEDA AYYILDIZ; | 2025-07-31 |
| 93 | Phase II Single Arm, Open Label Study of Artesunate for The Treatment of Human Papilloma Virus Positive High Grade Cervical Intraepithelial Neoplasia (CIN2/3) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in patients with pre-cancerous cervical intra-epithelial neoplasia (CIN2/3), to investigate if a course of treatment with oral artesunate can reverse pre-cancerous changes in the cervix and prevent the development and progression of invasive cancer. Findings from this study will increase our understanding of the effects of artesunate on CIN2/3 and if confirmatory inform future clinical studies. |
YOLANDA AUGUSTIN; | 2025-07-31 |
| 94 | Proof of Concept Assay Development of Point of Care Saliva Testing for High Risk-HPV Oral Cavity and Pharynx Cancers Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this research study is to determine if saliva and oral swab samples can be used to detect human papillomavirus in patients with cancer. In this study, the methods required to detect human papillomavirus will be developed and tested in samples collected from patients with oropharyngeal squamous cell carcinoma and compared to samples collected from participants without cancer. |
WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2025-07-31 |
| 95 | Self-Sampling to Optimize Anal Lesion Outcomes (SOLO) Pilot PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The investigators will test the cytological performance of a nylon-flocked swab at two insertion depths in the anus, 3 cm and 5 cm, to determine which insertion depth is better at collecting cells from the squamocolumnar junction (SCJ), an anatomic site that is particularly vulnerable to carcinogenic transformation. The investigators hypothesize that the 5 cm insertion will result in a higher quality specimen with cells from the SCJ. However, the deeper swab insertion may affect end user acceptability without increasing adequacy or quality. |
ALAN NYITRAY; | 2026-01-27 |
| 96 | Single-arm, Prospective Study of The Efficacy and Safety of Paiteling®Antibacterial Liquid in The Treatment of Persistent Cervical HR-HPV Infection PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The effectiveness of Patellin ® antibacterial solution in treating persistent cervical HR-HPV infection |
SONGLING ZHANG; | 2026-03-25 |
| 97 | A Pilot Study of Lenvatinib in Combination With Pembrolizumab in HPV-associated Recurrent Respiratory Papillomatosis Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This research study is studying Lenvatinib in combination with Pembrolizumab in people with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP). The names of the study drugs involved in this study are: * Pembrolizumab * Lenvatinib |
SARA PAI; | 2026-03-25 |
| 98 | A Phase Ib/II Multicenter Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of The Head and Neck: The PANTHERAS Related Papers Related Patents Related Grants Related Experts Highlight: Background: Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide. These cancers have different causes, with smoking/tobacco exposure and human papilloma virus infection being the most common. . When HNSCC occurs in people who are not infected with HPV, the cancers are more likely to return after treatment; when this happens, overall survival is only about 10 months, … |
VASSILIKI SALOURA; | 2025-07-10 |
| 99 | HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Individuals with experience of homelessness, substance use/addiction, transactional sex, and incarceration experience significant health inequities across a wide range of health conditions. This inequity includes cervical cancer with individuals in these populations less engaged with both routine human papillomavirus (HPV) vaccination and cervical cancer screening programmes, yet also at higher risk of developing cervical cancer. Opportunistic vaccination is recommended by the Joint Committee on Vaccination and Immunisation for ‘other at risk/vulnerable groups’ who may benefit (such as people with experience of transactional sex or incarceration) at clinical discretion. However, there is limited evidence on the feasibility, uptake, … |
CHRISTINE CAMPBELL; | 2025-07-25 |
| 100 | Comparison Between The Efficacy and Safety of Topical Podophyllin 25% Versus Cryotherapy in The Treatment of Anogenital Warts PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Human papilloma virus (HPV), is the major prevalent cause of sexually transmitted disease affecting genitalia, causing Condylomata Accuminata, also known as external genital warts or anogenital warts.¹ Occurring in men and women with a prevalence rate of 0.6-1.2% worldwide. It primarily affects those in the age range of 20-25 years. Human papilloma virus infections subclinically are primarily caused by either type HPV- 6 or HPV- 11. A vast variety of treatment options are available to treat CA , including immunomodulators ( imiquimod, purified protein derivative and the HPV vaccine), … |
NARJIS BATOOL; | 2025-05-13 |
| 101 | HPV Self-sampling in The General Population: Efficacy, Feasibility, Acceptability and Cost-effectiveness PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: A randomized controlled trial comparing three strategies for cervical cancer screening: direct mailing of HPV self-sampling kit (Outreach arm), choice between self-sampling or healthcare provider sampling (Choice arm), and standard care (control arm) in two French departments. |
AURÉLIE BERTRAND-BRICE; | 2025-07-23 |
| 102 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of The Head and Neck Related Papers Related Patents Related Grants Related Experts Highlight: To learn if TTI-101 can reduce the growth of HPV-negative squamous cell carcinomas of the head and neck when given before standard of care surgery. |
ANDREW SIKORA; | 2025-12-08 |
| 103 | Advancing Cervical Cancer Screening Through The Emergency Department PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Cervical cancer screening in the Emergency Department |
DAVID ADLER; | 2026-01-16 |
| 104 | Circulating Tumor HPV DNA Driven Adjuvant Treatment Deintensification After Transoral Surgery for HPV-Positive Squamous Cell Carcinoma of The Oropharynx PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a prospective phase II trial, designed to assess the efficacy and feasibility of adjuvant treatment deintensification guided by ctHPVDNA levels for patients with HPV+OPSCC who undergo transoral surgery and neck dissection. |
MICHAEL W. SIM; | 2025-07-31 |
| 105 | Prevalence of Human Papillomavirus (HPV) in A Healthy Population: A Feasibility Study of Oropharyngeal Cancer Screening PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: This study defines the prevalence of oral infection with high-risk human papillomaviruses (hrHPV) in individuals over 40 years of age in the Czech Republic. It also establishes an effective methodology for oropharyngeal carcinoma screening and optimization of screening and testing procedures. |
LYDIE IZAKOVIČOVÁ HOLLÁ; | 2026-02-13 |
| 106 | Self-sampling for HPV Screening: A Population-based Feasibility Study PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: To offer large-scale HPV self-sampling in Québec, it is essential to first demonstrate the most effective pathway for patient recruitment, proper sample collection, and safe continuity of care. Hypothesis: The hypotheses are that HPV self-sampling is a safe and effective screening method that can be implemented in Québec, and that it is a screening method appreciated by patients, reliable, and capable of increasing access to cervical cancer screening – … |
JESSICA RUEL LALIBERTÉ; | 2025-12-09 |
| 107 | Understanding The Human Papillomavirus Genotype Attribution and Disease Burden of Anal Cancer in China: A Multicenter Hospital-based Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: To demonstrate HPV prevalence and its genotype distributions in anal cancer in China and to describe demographic and clinical features of HPV-related anal cancer in China; To describe the epidemiological characteristics ,trends and of disease burden of anal cancer in China |
YING ZHENG; | 2026-02-12 |
| 108 | A Phase 2 Study of Vorinostat in Combination With Chemoradiation in Patients With Locally Advanced HPV Negative HNSCC Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to learn more about a drug called Vorinostat (an experimental drug) in combination with chemoradiation. The intention of this study is to learn if this drug is safe for the participants and whether this drug with chemoradiation is able to further increase the clinical efficacy of chemoradiation, which is an approved therapy. The main question it aims to answer is: How may Vorinostat interact with standard chemotherapy and radiation therapy in head and neck cancer? Participants will receive the study drug (Vorinostat) as a pre-treatment, followed by standard chemoradiation. |
KYUNGHEE BURKITT; | 2025-04-04 |
| 109 | A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab Vs Pembrolizumab Alone in First-Line Treatment of Unresectable Recurrent And/or Metastatic HPV16+ Head and Neck Squamous Cell Carcinoma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a global, multi-center, Phase 3 study that is randomized 2:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs. pembrolizumab monotherapy as first-line treatment in patients with unresectable recurrent or metastatic HPV16-positive HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1. |
PDS BIOTECHNOLOGY | 2025-12-11 |
| 110 | Role of Human Microbiome in Head and Neck Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms. |
SHI-LONG E LU; | 2026-02-24 |
| 111 | Strengthening HPV Vaccination and Adolescent Health Research Program (SHARP) in Tanzania PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Cervical cancer is a serious global public health problem, particularly in sub-Saharan Africa, where it is the leading cause of cancer in women, with around 70,722 new cases each year. Vaccination against human papillomavirus (HPV) prevents cervical cancer and is usually given to children around 9 to 15 years of age. HPV vaccination has been incorporated into many countries’ Expanded Programs on Immunization, but often faces optimization and uptake challenges. SHARP is an implementation research initiative in Tanzania, Nigeria, … |
POOJA SRIPAD; | 2025-08-13 |
| 112 | PREVENT: Practice-based Approaches to Promote HPV Vaccination in The Safety Net – Pilot Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will serve as one of the first to develop and test the effectiveness of strategies to promote HPV vaccination among diverse rural parents and caregivers of children ages 9-17 years in the Mountain West. Once implemented into practice, our intervention could significantly reduce disparities in the burden of HPV-associated cancers among rural populations in the United States. The proposed study will assess the feasibility of clinic-based outreach to increase vaccination rates for HPV at four community clinics in rural counties in Washington. |
DEANNA KEPKA; | 2026-03-20 |
| 113 | Vaccination Against Human Papillomavirus (HPV) in Women and Men After Stem Cell Transplantation PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases. For several reasons, these patients have a long-term immune deficiency due to the transplant itself (lack of immune reconstitution) and due to possible complications, primarily GvHD and its treatment. The risk of secondary malignancy in the long-term following an allogeneic bone marrow transplant is greatly increased, … |
STINA WICHERT; | 2025-06-05 |
| 114 | The Effect of Two Different Health Education Methods on Women’s HPV Knowledge, Cervical Cancer Health Belief and Screening Programme PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to evaluate the effect of two different health education methods (one based on motivational interviewing) on women’s HPV knowledge, cervical cancer health beliefs, and screening behaviors in women aged 30-65. A total of 96 healthy women who are registered at the Incirli Family Health Center in Ankara, meet the inclusion criteria, and volunteer to participate will be randomly assigned to three groups (32 participants per group). The control group will receive standard healthcare services. The first intervention group will receive three sessions of motivational interviewing-based health education on cervical cancer prevention through home visits, … |
SERPIL ÖZDEMIR; | 2025-09-02 |
| 115 | TweenVax: A Comprehensive Practice-, Provider-, and Parent/Patient-Level Intervention to Improve Adolescent HPV Vaccination PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This clinical trial compares the effect of a vaccine promotional intervention, TweenVax, to standard of care vaccination promotion practices on rates of human papillomavirus (HPV) vaccination in adolescents. HPV vaccination has been identified as a priority for cancer prevention and control by the Cancer Moonshot Blue Ribbon Panel, … |
ROBERT BEDNARCZYK; | 2025-08-05 |
| 116 | Pilot Observational Comparative Study Evaluating The Impact of The E-Bug Educational Programme on Parental Consent and HPV Vaccination Coverage During The National School-Based Vaccination Campaign in A Middle School in The Alpes-Maritimes PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a non-interventional observational pilot analysis assessing the possible impact of an educational programme (e-Bug) on parental consent and HPV vaccination uptake during the 2023-2024 and 2024-2025 national school-based HPV vaccination campaigns in France. The study focuses on one middle school in the Alpes-Maritimes department where teachers and the school nurse had been previously trained on HPV and used e-Bug educational resources in class as part of routine health education. No research-related intervention was conducted, … |
CENTRE HOSPITALIER UNIVERSITAIRE DE NICE | 2025-12-05 |
| 117 | A Study on The Pathogenesis and Determinants of Intravenous Leiomyomatosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to learn about the impact of HPV infection in women with intravenous leiomyomatosis(IVL). The main question it aims to answer is: Does HPV infection promote the development of IVL from uterine leiomyoma? Surgical sections and HPV-DNA test results will be collected in participants diagnosed with IVL or uterine leiomyoma. |
PEKING UNION MEDICAL COLLEGE HOSPITAL | 2025-02-28 |
| 118 | Phase II Trial of Atezolizumab and Tiragolumab for Patients With Detectable Circulating Tumor DNA After Definitive Treatment for HPV-positive Squamous Cell Carcinoma Related Papers Related Patents Related Grants Related Experts Highlight: A single-arm, phase II study for patients with detectable HPV CtDNA at 12 weeks or longer after completion of definitive therapy for non-metastatic, HPV+ squamous cell carcinoma. |
EMMA HOLLIDAY; | 2025-08-15 |
| 119 | Personalized, Scientifically Based Technologies in The Diagnosis and Treatment of SARS-CoV-2 As A Possible Cervical Cancer Risk Factor PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the diagnostic value of an electroacupuncture-based method for detecting viral persistence (human papillomavirus and SARS-CoV-2) in patients with cervical cancer. The study investigates whether persistent viral signatures can be identified through measurable electrodiagnostic responses at acupuncture points associated with organ systems affected by chronic viral infection. The goal is to assess the feasibility, reproducibility, and potential clinical relevance of this diagnostic approach in oncology patients. |
NAYLYA DJUMAEVA; | 2026-01-08 |
| 120 | Optimization of HPV-based Cervical Cancer Screening Strategies Among Women Living With HIV: Effectiveness and Implementation of Decentralized Approach Using A Mobile Team With HPV Testing in The Western Region of Cameroon PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. Yet, effective methods for screening and preventing CC are available. The recommanded approach for CC screening is based on multiple steps, including initial test to detect human papillomavirus (HPV) infection, visual inspection to identify women with HPV at risk for precancerous lesion and treatment when required. Dropout may occur at these different steps, … |
JOËLLE SOBNGWI; | 2025-12-02 |
| 121 | Conducting An Early Phase Clinical Trial to Assess for HPV Antigen Presentation Therapeutic Biological Product Mix Activity That Suggests The Potential for Clinical Benefits of HPV Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1. Treat Infection of Multiple HPV Virus Strains via Trained Immunity. 2. Activate human HPV Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the HPV virus protein antigens into small peptide fragments, and then clear HPV virus in vivo. |
HAN XU; | 2025-05-13 |
| 122 | Head and Neck Cancer Omics-integrated Precision MEdicine (HOPE) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Study Background and Rationale Head and neck cancer (HNC) is the sixth leading cause of cancer-related death, with over 650,000 new cases diagnosed worldwide each year. About 60% of patients are diagnosed at an advanced stage, and many experience recurrence or spread despite surgery, radiation, or chemotherapy. Major risk factors include tobacco and alcohol use, prior radiation therapy, … |
NAYEON CHOI; | 2025-09-24 |
| 123 | A Phase I Randomized Controlled Trial of Intratumoral Lidocaine Injection Before Transoral Robotic Surgery (TORS) and Neck Dissection for HPV-Associated Oropharyngeal Squamous Cell Carcinoma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Based on evidence that the local anesthetic lidocaine may have anticancer effects, this study will assess the safety and efficacy of intratumoral lidocaine injection at the time of direct laryngoscopy prior to TransOral Robotic Surgery (TORS) and neck dissection for oropharyngeal squamous cell carcinoma (OPSCC). The primary objective of the study is to determine if intratumoral lidocaine injection is safe and causes a major pathologic treatment effect in the primary tumor following surgical resection. The secondary objectives will be to determine if intratumoral lidocaine injection improves locoregional control rates, progression-free survival, metastasis-free survival, and overall survival compared to no injection. |
RYAN CAREY; | 2025-04-29 |
| 124 | Remote Resilience: Novel Applications of MHealth in Nicaragua’s Cancer Control Program PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to test an mHealth intervention for cervical cancer prevention in under-screened women ages 25-64 on the Caribbean Coast of Nicaragua. The mHealth intervention combines a patient-centered mobile app, a provider portal, and connectivity to the National Breast and Cervical Cancer Surveillance System (SIVIPCAN). The mHealth intervention will be combined with HPV primary screening for cervical cancer. The main questions it aims to answer are, … |
EMMA MCKIM MITCHELL; | 2025-04-10 |
| 125 | A Multicenter, Randomized, Double-Blind, Aluminum Adjuvant-Controlled Phase III Clinical Trial to Evaluate The Efficacy, Immunogenicity, and Safety of A Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E. Coli) in Chinese Males Aged 18 to 45 Years PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This phase III clinical trial was designed to evaluate the efficacy, immunogenicity and safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in Chinese males aged 18-45 years. |
JUN ZHANG; | 2025-07-31 |
| 126 | Reengineering Cervical Cancer Screening for The 21st Century: Joint Action for A Novel Up-to-date and Sustainable Screening Program PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Cervical cancer screening (CCS) is important to prevent and control cervical cancer (CC). In Portugal, CCS starts with the assessment of the presence of Human Papillomavirus (HPV) in cervical-vaginal samples, collected by a health professional. However, self-sampling (self-collection of vaginal samples by the participants in CCS), is being considered in several settings, aiming to improve participation in CCS, while also exploring its potential to reduce costs. The goal of this study is to learn how self-sampling could be introduced in the CCS program in Portugal, … |
NUNO LUNET; | 2025-04-23 |
| 127 | Phase II Trial of Surgery Followed By Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: The Minimalist Trial-2 (MINT-2) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\>90%) are caused by the human papillomavirus (HPV) and are often cured with current therapy. However, patients treated with surgery followed by postoperative adjuvant chemotherapy and radiation therapy (POA(C)RT) still experience substantial morbidity. In this highly curable disease, current clinical research interest is focused on investigation of de-escalated therapy, … |
DOUGLAS ADKINS; | 2025-04-15 |
| 128 | Concordance and Acceptability of Self-screening Compared to Screening Carried Out By A Health Professional for HPV, A Risk Factor for Anal Cancer, By Swab in People Living With HIV. A Randomized Controlled Crossover Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Comunity health actions are set up in populations of women aged 30 to 65 in vulnerable situations living in the outlying areas of Reunion Island. The idea is to evaluate those action on health |
EMMANUELLE THORE; | 2026-02-27 |
| 129 | Human Papillomavirus Self-sampling for Enhancing Cervical Screening During The War in Ukraine PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: In 2020, a cervical screening center was established in Zaporizhzhia (Ukraine), initiating a pilot project to evaluate the prevalence of HPV among women in Eastern Ukraine. The findings were intended to lay the groundwork for the Ukrainian Ministry of Health in establishing a structured national screening program. However, all efforts were halted due to the nearby armed conflict, situated just 40 kilometers from the border. The World Health Organization’s goal to eliminate cervical cancer globally has a gap when it comes to managing cancer control during crises like armed conflicts. We propose a demonstration project to assess whether a simpler, … |
SARA ARROYO MÜHR; | 2025-12-18 |
| 130 | De-escalation of Radiation Dose in HPV-associated Oropharyngeal Squamous Cell Carcinoma Utilising FMISO PET and Magnetic Resonance Imaging As Non-Invasive Biomarkers of Hypoxia (DE-RADIATE) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this prospective clinical trial is to determine if HPV-associated oropharyngeal squamous cell carcinoma that is non-hypoxic on FMISO PET can be successfully treated with a lower dose of radiation therapy. The main questions it aims to answer are: 1. What is the pathologic complete response rate in patients selected for radiation dose de-escalation and neck dissection? 2. What is the correlation between MRI and FMISO PET assessment of hypoxia before and during RT? 3. What are the acute and late toxicities in patients selected for radiation dose de-escalation? 4. What are the quality of life scores in patients selected for radiation dose de-escalation? 5. What are the local, regional and distant failure rates of patients selected for radiation dose de-escalation? Patients with cT1-2N1-2b (AJCC 7th edition) oropharyngeal tumours will undergo surgical resection of the primary tumour. Following this, they will be allocated to standard radiation therapy (70Gy with concurrent cisplatin chemotherapy) or de-escalation radiation therapy (30Gy with concurrent cisplatin chemotherapy) based on the results of FMISO PET. Patients with non-hypoxic tumours at baseline OR after two weeks of radiation therapy will be allocated to the de-escalated group. 3-4 months after completion of radiation therapy, all patients in the de-escalated group will undergo mandatory neck dissection to assess pathologic response. Researchers will assess the pathologic response rate after surgery in the de-escalation group. They will also compare the outcomes (oncological outcomes and quality of life) between the group receiving the standard treatment (70Gy) and the group receiving de-escalated radiation therapy (30Gy). |
ANNA LAWLESS; | 2025-07-30 |
| 131 | Negative HPV Test Results on Infinity/GeneXpert® With The Presence of A Late Amplification Signal: What Does This Mean ? PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this retrospective, single-center, observational study is to improve the diagnosis and interpretation of cervical cancer by better detection of epithelial lesions in the case of a late HPV PCR amplification signal rendered negative by routine laboratory testing using GeneXpert® technology. The various evaluation criteria are : * Presence or absence of lesions on cytological control following a negative HPV test with a late amplification signal on cervico-uterine and anal smear samples from patients seen in consultation at Brest University Hospital from 01/01/2022 to 30/06/2024 (after conventional PCR and genotyping). * Comparison of the GeneXpert® technique with the results of another conventional pan-genotypic Papillomavirus PCR test. |
CHRISTOPHER PAYAN; | 2026-04-02 |
| 132 | A Stepped-wedge, Cluster, and Randomized Trial to Evaluate Active Health Education Methods to Increase Human Papillomavirus Vaccine Coverage in Youth PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the impact of active health education methodologies on increasing adherence to the HPV vaccine among schoolchildren. The project will involve 196 schools across Brazil, encompassing a total of 5,000 students. A stepped-wedge implementation design will be applied, with clusters being randomized every two months to one of four interventions. Each intervention will be implemented in 48 schools. |
HOSPITAL ISRAELITA ALBERT EINSTEIN | 2025-11-18 |
| 133 | The Role of The Genital Tract Microbiota in Cervical Epithelial Cell DNA Methylation and The Increased Risk of Cervical Cancer Development PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to investigate the correlation between reproductive tract microbiota and DNA methylation in cervical epithelial cells, as well as its impact on the development of cervical cancer, through a paired case-control clinical study |
MUXUAN CHEN; | 2025-03-05 |
| 134 | Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With The Presence of High-grade Lesions And/or Anal Cancer 10 Years After Inclusion in The ANRS IPERGAY Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and/or anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and/or diagnosed since the end of participation in the ANRS IPERGAY trial. |
CAROLINE LASCOUX-COMBE; | 2025-12-04 |
| 135 | Conversations With AI Chatbots Increase Short-Term Vaccine Intentions But Do Not Outperform Standard Public Health Messaging PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to test whether short conversations with large language model (LLM) chatbots can persuade vaccine-hesitant parents to vaccinate their children against human papillomavirus (HPV). The study compares two chatbot styles to official public health information and to a no-message control. Parents of HPV-eligible children first complete a survey about their attitudes toward the HPV vaccine and their main concerns. They are then randomly assigned to read public health materials, have a three-minute conversation with either a default-style chatbot or a conversational-style chatbot tailored to their concern, … |
UNIVERSITY OF PENNSYLVANIA | 2025-08-20 |
| 136 | Strengthening HPV Vaccination and Adolescent Health Research Program (SHARP) in Ivory Coast PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Cervical cancer is a serious global public health problem, particularly in sub-Saharan Africa, where it is the leading cause of cancer in women, with around 70,722 new cases each year. Vaccination against human papillomavirus (HPV) prevents cervical cancer and is usually given to children around 9 to 15 years of age. HPV vaccination has been incorporated into many countries’ Expanded Programs on Immunization, but often faces optimization and uptake challenges. SHARP is an implementation research initiative in Tanzania, Nigeria, … |
ELAINE CHARURAT; | 2025-05-30 |
| 137 | Study on Novel Strategies for Cervical Cancer Screening Using Photoelectric Detection Combined with Epigenetic Procotol PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: A national multicenter, open randomized controlled study was conducted. It is planned to invite 30 multi-center units across the country to compete for enrollment, and each multi-center will enroll 140 patients meeting colposcopic indications (70 in the conventional group and 70 in the experimental group), totaling 4200 patients. Enrolled subjects were randomly divided into two groups. Methylation test + colposcopic biopsy was performed in the conventional group, and clinical follow-up was performed according to the methylation results; in the experimental group, methylation test + colposcopic biopsy +OITS was performed, … |
PEKING UNION MEDICAL COLLEGE HOSPITAL | 2025-03-10 |
| 138 | Dynamic Assessment of CtDNA in Patients With Cervical and Anal Canal Tumors to Optimize Follow-up and Clinical Outcomes in The Brazilian Unified Health System (SUS) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: After definitive radiotherapy (RT) treatment (with or without chemotherapy), cervical and anal canal neoplasms frequently exhibit disease persistence or recurrence. Due to the local inflammatory process post-treatment, response assessment by imaging (current gold standard) is limited, often necessitating multiple follow-ups and repeated invasive biopsies. Conventional follow-up is complex and costly, requiring equipment from secondary and tertiary services, trained radiologists, and patient exposure to radiation and contrast. In this context of human papillomavirus(HPV)-related neoplasms, recent studies have demonstrated the role of ctDNA (circulating tumor DNA) in assessing the risk of recurrence or disease progression, … |
MARIA DEL PILAR ESTEVEZ DIZ; | 2025-12-24 |
| 139 | Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to determine the provider- and practice-level characteristics that influence the impact of implementation strategies guided by practice facilitation in each clinical practice, to test whether the facilitator-driven provider- and practice-level implementation strategies increase provider recommendations and Human Papilloma Virus (HPV) vaccination rates and to evaluate implementation and future sustainability of the facilitator-driven implementation strategies across nine clinical practice sites |
DAISY Y. MORALES CAMPOS; | 2025-04-10 |
| 140 | A Phase II Single-arm Cohort Study Establishing The Effect of Antibiotic Treatment on Intratumoral Bacteria in Surgical Patients With Oral Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this phase II single arm clinical study is to evaluate the effect of antibiotics (metronidazole) and oral chlorhexidine (CHX) in reducing the bacteria load within tumors of patients undergoing surgery for oral cancer. |
NATALIE SILVER; | 2026-03-05 |
| 141 | Pembrolizumab for Orbital and Periocular Cutaneous Squamous Cell Carcinoma (cSCC) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This phase II trial studies how well pembrolizumab works in treating patients with orbital (eye socket) and/or periorbital (surrounding the eye socket) cutaneous squamous cell cancer (cSCC) that has spread to nearby tissue or lymph nodes (locally advanced) or has come back after a period of improvement (recurrent). Skin cancers that are close to the eye or on the eyelid often have more genetic (heredity) changes than other types of cancers. This means that the deoxyribonucleic acid (DNA) (the building blocks of the body that determine such things as the color of the hair) in tumor tissue has been altered compared to normal tissue. It is thought cancer cells with these DNA changes are more likely to respond to a type of drug called immunotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pembrolizumab is approved for patients with recurrent or metastatic cSCC not amenable (responsive) to cure by surgery or radiation. Giving pembrolizumab may work better in treating patients with locally advanced or recurrent orbital and/or periorbital cSCC. |
FRANCIS P WORDEN; | 2026-03-11 |
| 142 | A PRe-pOsT Interventional Study Evaluating Gardasil Nine-valent Human Papilloma Virus (HPV) Vaccine Humoral and Cellular Immune Responses in People With or Without HIV PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). Investigators will enroll BM-EABE with HIV and HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) and administer Gardasil9 at timepoints Day 0, Month 2, and Month 6. The immune response to the vaccine will be analyzed at Month 7 (1 month following the final vaccine dose). |
OMAR HARFOUCH; | 2025-03-07 |
| 143 | A Prospective, Single-center, Single-arm, Phase II Study of QL1706 Combined with Nine价HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study medications were used as follows: 1 cycle every 21 days (3 weeks) of the following regimen. Test drug: QL1706, HPV 9-valent vaccine QL1706: Dose: 5 mg/kg ; intravenous infusion (ivgtt), administered on Day 1 of each cycle and every 3 weeks (21 days). Treatment will continue until loss of clinical benefit, occurrence of intolerable toxicity, patient or physician decision to discontinue treatment, death of the patient receiving the experimental treatment, or completion of 2 years of dosing (35 dosing cycles), withdrawal of informed consent by the subject, pregnancy of the subject, noncompliance with protocol or procedural requirements, … |
BUHAI WANG; | 2025-03-28 |
| 144 | Human Papillomavirus Ends Here: A Multilevel Intervention to Increase Uptake of The HPV Vaccine Among Adolescents PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Develop, implement, and evaluate a culturally tailored multilevel intervention to increase uptake of the HPV vaccine among eligible patients ages 10-12 of the University of California, Davis Health Community Physician (UCDH CP) primary care practices using a randomized controlled trial design. |
JULIE HT DANG; | 2025-04-25 |
| 145 | A Dose Escalation Phase I Trial of The Safety and Immunogenicity of RG1-VLP, A Candidate Broadly Protective Vaccine for The Prevention of HPV-Associated Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This phase I trial tests the safety, side effects, and best dose of RG1-virus-like particle (VLP) in preventing human papillomavirus (HPV)-related cancers in women. RG1-VLP is a vaccine that aims to protect against rare HPV types not targeted by currently approved HPV vaccines. HPV is a common sexually-transmitted infection that can cause certain genital and oral cancers. RG1-VLP contains a protein of HPV type 16 (HPV16) with a slightly different structure than the licensed Gardasil-9 vaccine. Gardasil-9 is approved by the Federal Drug Administration to help protect against diseases caused by some types of HPV. Gardasil-9 also contains 9 different HPV proteins. Both vaccines contain alum to stimulate the immune system. The usual approach for the prevention of HPV-related cancers for patients who are at increased risk is to consider the currently approved HPV vaccine like Gardasil-9, as well as to be followed closely by their doctor to watch for the development of cancer via routine pap smears. This trial may allow researchers to find out whether the RG1-VLP vaccine can safely trigger an immune response against HPV in healthy women and if it is better or worse than the usual approach for the prevention of HPV-related cancers. |
REINHARD KIRNBAUER; | 2026-04-03 |
| 146 | Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: A Multicomponent Intervention for Safety Net Health Systems PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: To learn about the attitudes toward implementing self-collection among healthcare providers and staff, participants, and other stakeholders; and to inform the development of patient education and provider training materials to aid in the implementation of self-collection in clinical settings. |
JANE R MONTEALEGRE; | 2026-02-27 |
| 147 | A Pragmatic Trial on Actions For Collaborative Community Engaged Strategies for HPV PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The present study expands on the investigators’ earlier pilot study, outlined in ClinicalTrial ID#: NCT06010108. The Actions for Collaborative Community-Engaged Strategies for HPV (ACCESS-HPV), locally referred to as 4 Girls and Women (4GW) in Nigeria, seek to utilize a participatory crowdsourcing approach to enhance HPV prevention efforts among mother-daughter dyads. Specifically, the investigators aim to 1) develop a new combined HPV vaccination and HPV self-collection campaign for mothers/daughters using crowdsourcing open calls and learning community groups, 2) determine whether the co-developed final combined crowdsourced campaign will increase HPV vaccination rates among girls and promote HPV self-collection among mothers, … |
JULIET IWELUNMOR; | 2026-02-04 |
| 148 | People Living With HIV (PLWH), Oral and Oropharyngeal Cancer, and Health Equity: A Qualitative Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an exploratory qualitative study among People Living With HIV (PLWH) of diverse racial/ethnic and sexual and gender minority (SGM) identities to explore individual, interpersonal, and structural oral health equity factors that serve as barriers or facilitators of accessing oral health care, knowledge and perceptions of human papillomavirus (HPV) vaccination and Oral squamous cell carcinoma (OSCC) /Oropharyngeal squamous cell carcinoma (OPSCC), and to collect recommendations on how to increase access to oral health care and engage PLWH in OSCC/OPSCC prevention. |
ALEXANDRA HERNANDEZ LEVENSTON; | 2025-05-28 |
| 149 | Validation of A Lab-free Low-cost Screening Test for Prevention of Cervical Cancer: Automated Visual Evaluation PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to validate Automated Visual Evaluation (AVE), specifically the CINFinder version developed by DL Analytics, a point-of-care screening and triage diagnostic tool for cervical cancer based on the assessment of digital images through artificial intelligence. Several teams around the world have developed versions of AVE as a triage technology but none as a screening tool. |
KARLA ALFARO; | 2026-01-29 |
| 150 | The Effect of Health Belief Model-Based Motivational Interviews on Women’s HPV-DNA Testing According to The Precautionary Acceptance Process PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this randomized controlled study was to examine the effects of Health Belief Model Based Motivational Interviewing on HPV-DNA testing in women according to the Precautionary Acceptance Process. |
MUAZEZ KÜÇÜKKAYA; | 2026-02-03 |
| 151 | A Cluster Randomized Controlled Trial Testing Communication Strategies to Increase HPV Vaccination Intention: A Survey Experiment PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This research aims to identify communication strategies to improve the uptake of vaccines using an experimental design, focusing on the Human Papillomavirus (HPV) vaccine, which is highly effective in preventing HPV-related cancers. However, low HPV vaccination rates among adults remain a significant public health challenge. Although randomized controlled trials (RCTs) have demonstrated that interventions can increase vaccine uptake in children, few RCTs have been conducted on adults. To address this gap, a multidisciplinary investigative team with expertise in communication, medicine, nursing, and behavior-change intervention research, and a history of extensive collaboration, … |
FLORENCE MOMPLAISIR; | 2026-03-30 |
| 152 | The Effectiveness, Cost-effectiveness, and Budget Impact of Interventions to Improve The Delivery of Cervical Cancer Screening in Puerto Rico PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Cervical cancer incidence is increasing dramatically (2.5% per year) in Puerto Rico (PR), with increased occurrence of regional (1.7% per year) and distant (4.7% per year) stage cancer, which reflects a real increase and indicates missed screening opportunities. Unfortunately, 80% of cervical cancer cases diagnosed in PR occur among low-income women covered by Medicaid or Medicare, who also have a 70% greater likelihood of being diagnosed with cervical cancer. Cervical cancer screening uptake continues to decline in PR, particularly among low-income Medicaid enrollees, … |
ANA P. ORTIZ MARTINEZ; | 2025-04-29 |
| 153 | Measurable Residual Disease Detection Using Tumor-Informed CtDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of The Head and Neck PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment. |
DANIEL L. FADEN; | 2025-02-11 |
| 154 | Evaluation Of The Diagnostic And Prognostic Value Of Immunohistochemical Markers In Precancerous Lesions Of The Cervix PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study aims to evaluate the expression of certain proteins and their diagnostic and prognostic value in precancerous lesions of the cervix. |
PAOLO CASADIO; | 2025-02-28 |
| 155 | Unidos Contra El VPH: Screening Preference and Uptake of HPV Self-sampling Among Latinxs Along The US-Mexico Border PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the Unidos Contra el VPH study is to help find options to screen, or check, for cervical cancer that individuals can do at home to help prevent and detect cervical cancer early. Usually, … |
JESSICA CALDERON-MORA; | 2025-02-13 |
| 156 | Feasibility of Intravaginal Artesunate As Adjuvant HPV & Cervical Precancer Treatment Among Women Living With HIV in Kenya PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this randomized, placebo-controlled trial is to evaluate whether intravaginal artesunate pessaries (vaginal inserts) can be used as adjuvant therapy following thermal ablation to improve Human papillomavirus (HPV) treatment outcomes in Women Living with Human Immunodeficiency Virus (WLWH). The study will evaluate whether women who use artesunate will have higher HPV clearance at 6 months, compared to those who used a placebo. The study will also assess the safety, adherence, and acceptability of this treatment. 120 participants will be enrolled in the study. Participants will self-administer the study drug nightly for 5 days, take a week off, … |
CHEMTAI MUNGO; | 2025-12-17 |
| 157 | A Randomised, Double-blind, Placebo and Positive Controlled, Phase 2 Clinical Trial to Evaluate The Safety and Immunogenicity of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 9-45 Years PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants. |
YI MO; | 2025-12-17 |
| 158 | Phase 2 Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions (HPV2-2303) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a single-center, Phase II interventional study evaluating secondary HPV vaccination after treatment of high-grade cervical lesions. The study aims to estimate the rate of HPV clearance within two years following an initial positive HPV control test in women over 45 years of age who are chronic HPV carriers and have undergone treatment for high-grade intraepithelial cervical lesions, and who receive HPV vaccination. The study includes two cohorts: 1. Eligible patients who consent to vaccination will participate in a prospective, single-center, single-arm, interventional clinical trial (Category 2). 2. Non-vaccinated patients will be included in a non-interventional observational study, … |
CENTRE OSCAR LAMBRET | 2026-03-18 |
| 159 | Does HPV Education Affect Knowledge, Awareness, and Concern? PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized controlled study is being conducted between January and April 2025 at a Family Health Center in the Black Sea Region with 103 women (intervention group: 50, control group: 53) selected via randomizer.org. Participants complete pre-tests, receive HPV and cervical cancer prevention education, and take post-tests to evaluate the impact of the intervention. Keywords: HPV, education, knowledge, awareness, midwife. |
GIZEM ÇITAK; | 2025-08-08 |
| 160 | Knowledge,attitude &practice on Human Papilloma Virus Vaccination Among Healthcare Providers and General Population PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: – Cervical cancer is caused by persistent infection with certain strains of the human papillomavirus (HPV), which is a very common virus transmitted through sexual activity. – HPV infections can lead to the development of precancerous lesions on the cervix, which if left untreated, can progress to invasive cervical cancer over time. – Cervical cancer is the second most common cancer among women in Egypt, after breast cancer. – According to the latest available data, the age-standardized incidence rate of cervical cancer in Egypt is approximately 6.3 per 100,000 women. – However, … |
ABDELAAZIZ MOHAMED FATHI; | 2026-03-01 |
| 161 | Efficacy and Safety of Intralesional Injections of Candida Antigen, Polidocanol Sclerotherapy and Combined Candida Antigen With Polidocanol in Treatment of Patients With Common Warts PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the efficacy and safety of intralesional injections of candida antigen, polidocanol sclerotherapy and combined candida antigen with polidocanol in treatment of patients with common warts. |
HEBA SHAWKY OSMAN; | 2025-12-01 |
| 162 | RETRACE Study – Retrospective Observational Study Evaluating Disease Characteristics and Treatment Landscape of High-risk Locally Advanced (LA) or Recurrent / Metastatic (R/M) Cervical Cancer in Italy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Multicenter, Observational, Retrospective charts review. Observational study with descriptive purpose only. Retrospective data capture in consecutive patients diagnosed with CC who attended the Oncologic Clinics from Jan 2018 to Dec 2021 (using medical records, either electronic or not), inserted in eCRF and analyzed. |
MSD ITALIA S R L | 2025-03-10 |
| 163 | Screening Strategies Among High-risk Populations for Anal Cancer PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of the proposed research is to 1) examine the performance of emerging screening methods for anal high-grade squamous intraepithelial lesion (aHSIL), a precancerous condition of anal cancer, among populations at high risk for anal cancer and 2) characterize DNA methylation, immunologic response, and environmental factors associated with aHSIL. |
LISA FLOWERS; | 2025-09-08 |
| 164 | Optimizing Cervical Cancer Screening Strategies With HPV Testing Among Women Living With HIV in Cameroon: Feasibility, Acceptability, and Impact of A Single-visit Test and Treat Approach in A Hospital Center With An HPV Testing Platform PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. Yet, effective methods for screening and preventing CC are available. The recommanded approach for CC screening is based on multiple steps, including initial test to detect human papillomavirus (HPV) infection, visual inspection to identify women with HPV at risk for precancerous lesion and treatment when required. Dropout may occur at these different steps, … |
JOËLLE SOBNGWI; | 2025-09-16 |
| 165 | The Femscope Calm Collect Device to Obtain Cervical Cells for Cancer Screening PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to determine if cervical cells collected by the Femscope Calm Collect Device in women (sex assigned at birth) of adult age are the same quality and quantity as the cervical cells collected by the traditional brush method for cervical cancer screening. The main questions it aims to answer are: 1. Increase the number of women who get screened for cervical cancer. 2. Improve patient acceptance of getting cervical screening on a routine basis. 3. Decrease pain and discomfort for patients having a PAP smear procedure. Participants will * Have two vaginal exams to collect cervical cells. * State decreased pain and discomfort for patients having a PAP smear procedure. * The Femscope Calm Collect Device (FCCD) will be more comfortable for the patient as measured by a patient satisfaction survey comparing the FCCD and the traditional speculum method of obtaining cervical cells. |
MARILYN S FILTER; | 2025-10-27 |
| 166 | Message Framing in HPV Vaccination Decision: A Survey Experimental Study Among Chinese Male College Students PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to determine if different risk communication strategies can increase the intention to receive the HPV vaccine among male college students in China. The study focuses on male college students aged 18-25 years, … |
BO YAN; | 2025-07-16 |
| 167 | STRatIfication of Vulvar Squamous Cell Carcinoma By HPV and P53 Status to Guide Excision PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is being done to answer the following question: Are there types of early-stage vulvar cancer that require either less or more treatment than the usual approach? |
CANADIAN CANCER TRIALS GROUP | 2026-03-10 |
| 168 | ReMARk: A Multi-level Intervention Addressing Disparities in Rural HPV-related Cancer Prevention: Part 3- Evaluation PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: There are three main objectives of the protocol. First, we will evaluate the added clinical- and cost- effectiveness of parent-targeted motivational aids (reminder/recall and phone-based MI) alone and when combined with community-targeted healthcare access assistance beyond the effects of clinician-targeted training. Second, we will estimate the differential effectiveness of the implementation strategies by patient-level factors (age, race/ethnicity, sex, distance from home to clinic, social vulnerability). Third, we will measure moderation of implementation strategy effectiveness by clinic-level factors (HPV vaccination priority, resources, clinic visit types, scheduling practices, and implementation success). Within 11 rural North Central Florida counties, … |
STEPHANIE STARAS; | 2025-09-09 |
| 169 | Single-Center Evaluation of The Clinical and Radiological Benefit of AHCC® in Combination with Standard of Care Treatment for HPV-Positive Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell Carcinoma. These are subjects who have undergone surgery or will be undergoing surgery. |
RUPALI NABAR; | 2025-03-27 |
| 170 | Community, Home-based Education, Screening Services (CHESS) Strategy to Increase Cervical Cancer Control Access for HIV-Positive Women in Nigeria PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to focus on adapting and implementing a program to promote HPV and cervical cancer (CC) screening and follow-up treatment for HIV-positive women, with three specific aims: * Adaptation: Use stakeholder deliberation to tailor the successful MoMent program for this population. * Implementation and Assessment: Deploy the adapted MoMent program and evaluate its reach, effectiveness, adoption, and fidelity. * Evaluation: Conduct a post-implementation process evaluation to identify barriers and facilitators to the program’s maintenance and sustainability. |
LISA FLOWERS; | 2025-08-06 |
| 171 | Enhancing Health Literacy Through Artificial Intelligence-Powered Chatbot: A Randomized Controlled Trial on Addressing Human Papillomavirus Vaccination Misinformation Among Caregivers in Japan PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to learn if an innovative digital artificial intelligence (AI)- based communication tool works to enhance health literacy among Japanese caregivers regarding Human Papillomavirus (HPV) vaccination. Participants will: – Answer a pre-intervention survey, get information regarding HPV vaccination from an AI-based chatbot or leaflet, and answer a post- intervention survey. – Continue interacting with the chatbot or leaflet for two weeks. – Answer a follow-up survey. |
KANA KOBAYASHI; | 2025-12-31 |
| 172 | Effect of Patient Navigation-based Health Management Model on Quality of Life and Sexual Function After LEEP in Patients With Cervical Lesions PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Cervical cancer poses a significant threat to women’s health and is a crucial public health issue. Early detection and treatment of cervical lesions and standardized management have emerged as essential pillars in the Global Cervical Cancer Elimination. The loop electrosurgical excision procedure (LEEP) is widely employed as a preferred approach for the diagnosis and treatment of precancerous cervical lesions and early invasive cervical cancer. Patients with high-grade cervical lesions are more prone to experiencing sexual dysfunction and psychological disorders after LEEP, attributed to the unique surgical site, physiological alterations, and psychological stress during the postoperative recovery process, … |
REN WENHUI; | 2025-12-31 |
| 173 | Knowledge of 18-19 Years Old About Papillomavirus and HPV Vaccination PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Today, cancers associated with papillomavirus infection affect 6,300 new people each year in France, men and women combined. The papillomavirus vaccine is currently the only vaccine that protects against HPV-associated cancers. However, in its report on vaccination coverage for 2024, Santé Publique France reveals that 41.5% and 37.4% of the 18- and 19-year-old French population respectively have a complete vaccination schedule. Information, … |
UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE | 2026-02-18 |
| 174 | Enhancing Health Literacy Through Artificial Intelligence-Powered Chatbot: A Randomized Controlled Trial on Addressing Human Papillomavirus Vaccination Misinformation Among Caregivers in Japan PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to learn if an innovative digital artificial intelligence (AI)-based communication tool works to enhance health literacy among Japanese caregivers regarding Human Papillomavirus (HPV) vaccination. Participants will: – Answer a pre-intervention survey, get information regarding HPV vaccination from an AI-based chatbot or leaflet, and answer a post-intervention survey. – Continue interacting with the chatbot or leaflet for two weeks. – Answer a follow-up survey. |
LEESA LIN; | 2025-12-31 |
| 175 | STRatIfication of Vulvar Squamous Cell Carcinoma By HPV and P53 Status to Guide Excision: STRIVE Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Vulvar cancer affects the external genitalia of women. This type of cancer is uncommon, arising mostly in older women and has been neglected in research and clinical trials. Over the recent years, investigators have learned that the most common type of vulvar cancer; vulvar squamous cell carcinoma (VSCC) develops from pre-cancerous lesions via different pathways. One pathway is associated with human papillomavirus (HPV) infection, and another is related to chronic inflammatory skin conditions (and not HPV). The VSCCs arising from these two principal pathways; HPV- associated (HPV A) and HPV-independent (HPV I), behave differently with different risks of recurrence, … |
JESSICA MCALPINE; | 2026-02-03 |
| 176 | Persistent Oral HPV Among Diverse PLWH: A Pilot Study to Evaluate The Feasibility and Acceptability of Testing for Oral HPV DNA Infection With Mail-delivered Sample Collection Kits PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: People living with human immunodeficiency virus (PLWH) have an estimated 1.6-6.0 times increased risk of developing oropharyngeal cancer (OPC) compared with individuals in the general population. 70% of OPCs are caused by human papillomavirus (HPV), and PLWH also have an increased prevalence of oral HPV infection. Disparities by race/ethnicity also include a later stage of diagnosis and less frequent cancer-directed treatment for members of ethnic minority groups. There is little known regarding the racial/ethnic differences in oral HPV infection, persistence of oral HPV infection, or progression of oral HPV infection to OPC among PLWH. This is an observational, … |
ALEXANDRA HERNANDEZ LEVENSTON; | 2025-08-01 |
| 177 | Culturally Targeted Messaging and Parental Receptivity to The Human Papillomavirus Vaccine PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if culturally targeted messaging about the human papillomavirus (HPV) increases receptivity to the HPV vaccine among African American parents of vaccine-eligible daughters. The main question it aims to answer is: • Does culturally targeted messaging increase African American parents’ intentions to vaccinate their daughter against HPV? Research will compare culturally targeted messaging to general, educational messaging and no messaging. Participants will: * View culturally targeted messages, education-only messages, … |
TODD LUCAS; | 2026-03-13 |
| 178 | PREPAP Study: Tolerance and Effectiveness of The Monoterpenoid Zinc Tetra-ascorbo-camphorate (C14) on The Genital Load of Oncogenic HPV (HR-HPV) and Precancerous Cervical Lesions: Research With Direct Individual Benefit PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The zinc monoterpenoid tetra-ascorbo-camphorate possesses broad-spectrum anti-viral properties in vitro, particularly against HIV, HSV and HPV. Its C14 formulation could be a promising candidate for in vivo clinical evaluation as a potential microbicide or therapeutic drug. The aim of this clinical trial is to determine whether C14 is effective in reducing the genital viral load of HR-HPV and in treating low-grade dysplastic lesions of the cervix. It will also determine the tolerability of C14. The main questions to be answered by the clinical trial are as follows: Does C14 reduce the genital HR-HPV viral load in participants with persistent HR-HPV infections? What medical problems do participants experience when taking C14? Researchers will compare C14 to a placebo (a similar substance that contains no drug) to see if C14 is effective in reducing genital C14 viral load and in treating low-grade dysplastic lesions of the cervix. Participants will receive four monthly treatments (5ml of C14 dissolved in distilled water administered twice daily [morning and evening] for seven days via vaginal syringe during the follicular phase) of C14 or placebo for 4 months and visit the clinic once every 2 weeks for examinations and tests. They will keep a diary of their symptoms and the number of times they keep the hospital appointment. |
SERGE TONEN-WOLYEC; | 2025-07-15 |
| 179 | Efficacy and Safety of Platelet-rich Plasma, Metformin and Cryotherapy in Treatment of Non-genital Warts PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: 1. Evaluation of the efficacy and safety of intralesional injection of autologous platelet-rich plasma in treatment of various types of cutaneous non genital warts 2. Evaluation of the efficacy and safety of intralesional injection of metformin in treatment of various types of cutaneous non genital warts 3. Comparing the efficacy and safety of intralesional injection of autologous platelet-rich plasma and intralesional injection of metformin with that of cryocautery in treatment of various types of cutaneous non genital warts. |
AYA GAMAL ABD EL-WAHAB MAHMOUD; | 2025-04-01 |
| 180 | Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this study is to assess the use of and satisfaction with the ECA-HPV intervention over a 16-month period, its ability to increase HPV vaccination, and the comparative effectiveness of clinic notification and adolescent ECA components on these factors. |
MICHAEL PAASCHE-ORLOW; | 2025-07-15 |
| 181 | Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening Accuracies (LiVes LLC Study) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study will examine both Human papillomavirus (HPV) vaccine effectiveness and Primary high-risk HPV PHS screening triage strategies in women living with HIV (WLHIV) by partnering with the Pediatric HIV/AIDs Cohort Study (PHACS) led, in part, by our investigative team. Among WWH, … |
ANNA-BARBARA MOSCICKI; | 2025-08-29 |
| 182 | An Open-Label, Single-Arm, Phase 1/2 Dose-Escalation Trial of Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin-Alpha) for Idiopathic CD4 Lymphopenia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Idiopathic CD4 lymphopenia (ICL) is a syndrome characterized by low levels of certain immune cells called CD4 T cells. The low CD4 T cells renders people with ICL prone to many types of severe infections, autoimmune diseases, and cancers. Although these infections and diseases can be treated whenever occur, … |
ANDREA LISCO; | 2026-03-09 |
| 183 | Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: Each year in the U.S., ≥20,000 women and 14,000 men are affected by HPV-related cancers, including cervical and oropharyngeal cancer. However, in 2020, only 59% of U.S. adolescents aged 13-17 were up-to-date for HPV vaccination, and rates for 11-12 year olds, the primary target age group for HPV vaccination (when the immune reaction is better and before exposure to HPV infection), are even lower. Standing orders (written protocols that authorize designated members of the healthcare team to vaccinate without first obtaining a patient-specific physician order) have been shown to work in inpatient settings and for adults, … |
CYNTHIA RAND; | 2025-10-24 |
| 184 | Clinical Evaluation of Self-collected Urine Samples for The Detection of Human Papillomavirus in Males PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Human papillomavirus (HPV) infection is one of the most prevalent viral infections of the genital tract, primarily transmitted through sexual contact. Research indicates that individuals engaging in sexual activity have a lifetime probability of HPV infection as high as 85% to 90%. While extensive and in-depth investigations have been conducted on HPV infection in women, epidemiological studies focusing on male HPV infection remain relatively scarce. Many men with HPV are asymptomatic; reports suggest that approximately 10.5% of men in China are infected with HPV, … |
ZHAO YONGPING; | 2025-04-30 |
| 185 | Evaluation of Local Hyperthermia for The Treatment of Cervical Intraepithelial Neoplasias 3 Months After Treatment: A Multicenter, Single-blind, Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Human papillomavirus(HPV) infect epithelial cells and have the capacity to stimulate cell abnormal hyperplasia, especially by those high-risk HPV types. HPV vaccine primarily targeting HPV6/11/16/18 has been available and makes it possible to prevent cervical cancer. However, a large population was left unvaccinated, specifically for those aged ones. In clinic, … |
GAO XINGHUA; | 2025-08-13 |
| 186 | Integrated Service Delivery to Improve Adolescent Health and HPV Vaccination in Lao PDR: A Quasi-Experimental Mixed-Methods Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to find out if adding HPV vaccination to adolescent health services works to increase HPV vaccine uptake in 10-13-year-old girls in Laos. The study will also look at the effects of adding HPV vaccination on the use of other health services in 10-13-year-old boys and girls. The main questions the study aims to answer are: 1. Does adding HPV vaccination to adolescent health services increase HPV vaccine uptake in girls aged 10-13 years compared to girls who only receive standard HPV vaccination services? 2. Does adding HPV vaccination to adolescent health services increase the use of other health services in 10-13-year-old adolescent boys and girls compared to adolescents who only receive standard HPV vaccination services? 3. What are the barriers and facilitators to using the combined intervention in Laos? 4. What are the opinions of adolescents, caregivers, healthcare providers, and other stakeholders on the combined intervention? 5. How much does it cost and how well it works to combine HPV vaccination with adolescent health services, as opposed to providing HPV vaccination alone? Researchers will compare a combined intervention to standard HPV vaccination services to see if the combined intervention works to increase HPV vaccination uptake and the use of other health services. The combined intervention includes HPV vaccination given at schools, health facilities, and through community outreach. It also includes education on sexual and reproductive health, counseling, and other health services. Participants in the combined intervention group will: 1. Receive the HPV vaccine at school or at a health facility. 2. Take part in group discussions about sexual and reproductive health. 3. Take part in individual counseling sessions. 4. Use other health services as needed. Participants in the comparison group will receive standard HPV vaccination services, including: • HPV vaccination given at schools, health facilities, and through community outreach. |
THET LYNN; | 2025-03-12 |
| 187 | Human Papillomavirus Vaccine Integrated Service Implementation Research in Cameroon PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this implementation research study is to understand whether a package of community-based interventions can increase access to and uptake of the human papillomavirus (HPV) vaccine among very young adolescent girls and boys in the North and Far North Regions of Cameroon. The main questions this study aims to answer are: – Can a package of community-based interventions increase delivery of routine HPV vaccination to boys and girls aged 9-13 in Cameroon’s North and Far North Regions? – What is the acceptability, feasibility, cost, … |
WILFRED MBACHAM; | 2025-12-01 |
| 188 | Human Papillomavirus Vaccine Integrated Service Implementation Study in Ethiopia (HPV-VISION) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this implementation research study is to understand whether a package of community-based interventions can increase access to and uptake of the human papillomavirus (HPV) vaccine among very young adolescent girls in rural Ethiopia. The main questions this study aims to answer are: – Can a package of community-based interventions increase delivery of routine HPV vaccination to girls aged 9-14 in rural Ethiopia? – Is an intervention model that incorporates strategies that address gender norms and gender-specific barriers more effective at increasing delivery of routine HPV vaccination than a model that does not explicitly address gender? – … |
WAKGARI DERESSA; | 2026-03-01 |
| 189 | The Relationship Between Anal High-Risk HPV (Hr-HPV) Infection, Anal High-Grade Squamous Intraepithelial Lesions (HSIL), and The Anal Microbiome Among Three Distinct Populations of Hispanic People Living With HIV (PLWH) in California, Mexico and Puerto Rico PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study evaluates if there is relationship between the kinds of bacteria living in the anus (also known as the anal microbiome) and the risk of human papillomavirus (HPV) infection or HPV-related pre-cancer (high-grade squamous intraepithelial lesions or HSIL) in Hispanic people living with HIV (PLWH) in Puerto Rico, Mexico and California |
JOEL PALEFSKY; | 2025-12-10 |
| 190 | Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This trial tests how well personalized ultra fractionated stereotactic adaptive radiotherapy (PULSAR) works together with HyperArc© radiation treatment planning technology for palliative (holistic pain and symptom control) tumor control in patients with primary or recurrent, localized or metastatic head and neck cancer (HNC) who are ineligible for or decline standard of care treatment. Researchers want to evaluate if using HyperArc and PULSAR together will deliver higher, possibly more effective doses, … |
TRAVIS COURTNEY; | 2026-02-05 |
| 191 | Evaluation of The Impact of A HPV Vaccination Talk with Third Grade Students on Their Papillomavirus Vaccination Coverage PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a prospective pragmatic study to assess the impact of a HPV vaccination talk in secondary school on actual vaccine dispensing in test communes compared with control communes. The talk consist on a briefing on the importance of vaccination. This is a controlled study, since two communes will benefit from the HPV vaccination talk, while the other two will serve as controls without set up of the HPV vaccination talk. The set up of this presentation will be open-label. |
HOPITAL FOCH | 2025-10-01 |
| 192 | HPV Self-Collection Program PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of the study is to develop, pilot, and analyze the effectiveness of HPV self-collection programs which will be used to follow up among women overdue for cervical cancer screening. The investigators will develop protocols for in-clinic and home-based HPV-self-collection programs and follow-up system for HPV-positive tests for community health centers and/or clinics. The program is meant to mail HPV-self-collection kits to women who are due and/or overdue for cervical cancer screening and the program is also meant to present women seen in clinic with a self-collection option for screening alongside a Pap test option. The research team will develop related informational resources on how to complete the test as well as information on screening options. The study will neither experiment nor test the effectiveness of the self-collection process nor the assay of specimens for HPV and high-risk HPV strains. It is not a clinical investigation to assess the safety or effectiveness of a medical device. The study is implementation science and seeks to find optimal ways to implement this World Health Organization recommended screening option. |
DEANNA KEPKA; | 2026-02-20 |
| 193 | Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living with HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study is evaluating immediate or delayed single-dose nonavalent HPV vaccination among women living with HIV who received prior HPV vaccination. |
RUANNE BARNABAS; | 2026-01-12 |
| 194 | Acceptability of The Human Papillomavirus (HPV) Vaccine and Anal HPV in Transgender Women (TGW) and Men Who Have Sex With Men (MSM): A Pilot Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Protocol Title: Acceptability of the Human Papillomavirus (HPV) Vaccine and Anal HPV in Transgender Women (TGW) and Men Who Have Sex with Men (MSM): A Pilot Study. |
FLORENCIA MARINA CAHN; | 2025-06-13 |
| 195 | Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP in Nigeria) PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn whether adding adolescent health services to routine government health programs can increase Human Papillomavirus (HPV) vaccination coverage among 9-year-old girls and improve use of other health services by adolescents in Nigeria. The main questions it aims to answer are: Does offering an integrated package of adolescent health services increase the proportion of 9-year-old girls who receive the HPV vaccine? Does this package increase use of other services such as reproductive health counseling, nutrition and vision screening, mental health services, … |
CHIZOBA WONODI; | 2026-01-07 |
| 196 | Comparisons of The Effects and Clinical Outcomes of CH2 Vaginal Gel Versus Placebo on CIN1 With High-risk HPV Patients: A Prospective Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: In Taiwan, Pap smear screen has been offered every year for women over 30 years old since 1995. The incidence of cervical invasive cancer decreased from 25/100,000 person in 1995 to 7.0/100,1000 person in 2016. In contrast, the incidence of pre-cancerous lesions increased gradually. According to ASCCP, observation and repeated cytology in 6-12 months is recommended in colposcopy-diagnosed CIN1 patients. Most of the low-grade lesions regressed spontaneously without treatment; 49 percent of CIN1 regressed to negative in six months, and 70 percent regressed in 12 months. Emerging evidence suggests associations between the composition of the vaginal microbiota (VMB), … |
CHI HAU CHEN; | 2025-11-19 |
| 197 | NCI Cervical Cancer ‘Last Mile’ Initiative ‘Self-Collection for HPV Testing to Improve Cervical Cancer Prevention’ (SHIP) Trial LMI-001-A-S02 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. It is known to cause a variety of cancers including cancer of the cervix. Even though there are ways to detect cervical cancer early, … |
VIKRANT V SAHASRABUDDHE; | 2025-12-15 |
| 198 | NCI Cervical Cancer ‘Last Mile’ Initiative ‘Self-Collection for HPV Testing to Improve Cervical Cancer Prevention’ (SHIP) Trial LMI-001-A-S03 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. HPV is known to cause a variety of cancers including cervical cancer. Even though there are ways to detect cervical cancer, … |
VIKRANT V SAHASRABUDDHE; | 2025-12-30 |
| 199 | Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women, with an estimated 604,000 new cases and 342,000 deaths worldwide in 2020. Rwanda is among countries with a high burden cervical cancer, with an annual incidence of 28.2/100,000 women (1,229 new cases in 2020) and a mortality rate of 20.1/100,000 (829 deaths in 2018) according to WHO (IARC 2020). Cervical cancer is almost completely preventable because of the highly effective primary (HPV vaccine) and secondary (HPV screening) prevention measures. However, … |
FRANCOIS UWINKINDI; | 2026-03-30 |
| 200 | Phase III Randomized and Double-blinded Trial of De-escalated Radiation in FMISO PET-selected Good Risk Versus Standard of Care Radiation in Unselected HPV Positive Oropharyngeal Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The researchers are doing this study to find out if a personalized approach to chemoradiation therapy (which may include a lower dose of radiation) is as effective as the standard chemoradiation therapy in people with HPV-positive throat cancer. Other purposes of this study include looking at the following: * Whether a lower dose of radiation in combination with standard chemotherapy causes fewer side effects than the standard dose of radiation therapy in combination with standard chemotherapy * How the study approaches (lower dose of radiation therapy + standard chemotherapy and standard dose of radiation therapy + standard chemotherapy) affect participants’ quality of life. The researchers will measure quality of life by having participants fill out questionnaires. |
NANCY LEE; | 2026-02-04 |